

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Convened by the National Cancer Policy Forum in collaboration with the
Forum on Mental Health and Substance Use Disorders

A WORKSHOP

NATIONAL ACADEMIES Sciences
Engineering
Medicine

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Day 1 March 17 • 8:30AM – 5:30PM ET

Day 2 March 18 • 8:30AM – 11:30AM ET


National Academy of Sciences Building – Lecture Room
2101 Constitution Ave, NW
Washington, DC 20418

Link to view the live webcast:

[Addressing the Impact of Tobacco and Alcohol Use on
Cancer-Related Health Outcomes: A Workshop | National Academies](#)

Workshop Location

The National Academies NAS Building – Lecture Room
2101 Constitution Ave, N.W.
Washington, DC 20418




Uber/taxi/Lyft: The NAS building is across the street from The State Department (C Street entrance), or look for the Einstein statue (Constitution Ave. entrance)!

Entering from Constitution Ave NW: Please check in with the security guard at the desk and proceed straight into the Great Hall. Turn right and walk up the few stairs into the Gallery; The East Court/Lecture Room will be on your right.

Entering from C Street NW: Please check in with the security guard at the desk, walk through the lobby and hall, then turn left into the Great Hall. Turn left, walk up 3-4 stairs into the Gallery, and the East Court/Lecture Room is on your right.

See the National Academy of Sciences Building floor plan below.



March 17, 2025

Dear Colleagues,

Welcome to the National Academies of Sciences, Engineering, and Medicine workshop on *Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes*, convened by the National Cancer Policy Forum in collaboration with the Forum on Mental Health and Substance Use Disorders.

This workshop will examine the current state of the science and explore strategies to reduce the use of tobacco and alcohol to lower cancer risk and improve health outcomes. Workshop presentations and discussions will provide an overview of research on the effects of tobacco and alcohol use on cancer-related health outcomes; examine effective tobacco control policies and successful strategies for alcohol policy; evidence-based interventions for tobacco cessation and to help patients reduce alcohol use; and discuss gaps in evidence, practice, and policy for tobacco and alcohol use. We hope that this workshop will spur progress towards a deeper understanding of the effects of both tobacco and alcohol and their synergistic effects on cancer incidence and outcomes, improved education on the impacts of alcohol and tobacco, and development of clinical guidelines for cancer patients to mitigate the risks of alcohol and tobacco use.

Please note that it is essential to the National Academies mission of providing evidence-based advice that participants in all our activities avoid political or partisan statements or commentary and maintain a culture of mutual respect. The statements and presentations during our activities are solely those of the individual participants and do not necessarily represent the views of other participants or the National Academies.

We welcome your involvement in the workshop. Please use the microphones in the room or the chat box on our [website](#) to ask questions. Also, please mention your name and affiliation and keep your questions or comments very brief. A proceedings of the workshop will be published by the National Academies Press and may incorporate your comments and ideas. Archived presentations and videos from the workshop will also be available on the website.

We look forward to your involvement in this workshop.

Sincerely,

S. Gail Eckhardt, MD, FASCO
Associate Dean of Experimental Therapeutics
Baylor College of Medicine
Associate Director of Translational Research
Dan L Duncan Comprehensive Cancer Center

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Deputy Director for Clinical Affairs
Yale Cancer Center and Smilow
Cancer Hospital
Assistant Dean for Translational Research
Yale School of Medicine


Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes: A Workshop

March 17-18, 2025

National Cancer Policy Forum
Forum on Mental Health and Substance Use Disorders

[Workshop Website](#)

National Academy of Sciences Building
2101 Constitution Ave NW
Washington DC 20418



WORKSHOP AGENDA

MONDAY, MARCH 17, 2025 EASTERN TIME ZONE	
8:00 am	Breakfast and Registration (30 minutes)
8:30 am	Welcome and Introductory Remarks (10 minutes) Roy Herbst and S. Gail Eckhardt, Planning committee co-chairs
8:40 am	Keynote Presentation (~20 minutes) - David Berrigan, National Cancer Institute (<i>participating virtually</i>) A Patient Perspective (~10 minutes) - Gwen Darien, Patient Advocate Foundation
9:10 am	Session 1: Overview of Research on the Effects of Tobacco and Alcohol Use on Cancer-Related Health Outcomes (~1 hour, 45 minutes) <i>Co-Moderators:</i> <i>Elena Martínez, University of California, San Diego</i> <i>S. Gail Eckhardt, Baylor College of Medicine</i> <i>Session Objective:</i> To provide an overview of the current research on the effects of tobacco and alcohol use on cancer-related health outcomes including the synergistic effects and examine the differences in outcomes. Overview of Modifiable Risk Factors (~10 minutes) - Farhad Islami, American Cancer Society Epidemiology of Tobacco and Cancer (~10 minutes) - Neal Freedman, National Cancer Institute (<i>participating virtually</i>) Epidemiology of Heavy Alcohol Consumption and Cancer (~10 minutes) - Jo Freudenheim, University at Buffalo Global Perspective on the Cancer Burden Attributable to Tobacco and Alcohol Consumption (~10 minutes) - Harriet Rungay, International Agency for Research on Cancer (<i>participating virtually</i>) Research on the Synergistic Effects of Tobacco and Alcohol (~10 minutes) - Stephen Hecht, University of Minnesota

	Research on the Biological Etiology of Heavy Alcohol Use Disorder (~10 minutes) - Hang Zhou, Yale School of Medicine Indigenous Community Perspective (~10 minutes) - Melissa Buffalo, American Indian Cancer Foundation Panel Discussion (~35 minutes) Session Speakers and: - David Berrigan, National Cancer Institute (<i>participating virtually</i>)
10:55 am	Break (15 minutes)
11:10 am	Session 2: Tobacco Control Policy: Lessons Learned and Next Steps (~1 hour, 20 minutes) <i>Co-Moderators:</i> Nigar Nargis, American Cancer Society Gwen Darien, Patient Advocate Foundation <i>Session Objective:</i> To examine the effective policies known to prevent tobacco use and how communities are addressing tobacco use to lower cancer risk. Overview of Evidence-Based Tobacco Control Policies (~10 minutes) - Geoffrey Fong, University of Waterloo Youth Tobacco Prevention and Behavior Change (~10 minutes) - Jessica Barrington-Trimis, University of Southern California Restricting the Sales and Marketing of Tobacco Products to Reduce the Public Health Burden of Tobacco (~10 minutes) - Kurt Ribisl, University of North Carolina Gillings School of Global Public Health Public Health Policy (~10 minutes) - Ella Greene-Moton, American Public Health Association (<i>participating virtually</i>) Outcomes of Smoking Cessation Treatment After a Cancer Diagnosis (~10 minutes) - Graham Warren, Medical University of South Carolina (<i>participating virtually</i>) Panel Discussion (~30 minutes)
12:30 pm	Lunch (1 hour)
1:30 pm	Session 3: Developing Alcohol Policy: What is Known, What Can be Learned from Tobacco Policy, and What's Next? (~1 hour, 50 minutes) <i>Co-Moderators:</i> S. Gail Eckhardt, Baylor College of Medicine Roy Herbst, Yale University <i>Session Objective:</i> Identify the successes and challenges of tobacco control policy and information gleaned from alcohol use research to design and deploy best practices for reducing the impact of heavy alcohol use on cancer-related health outcomes. Price and Taxation of Alcohol: Lessons Learned from Tobacco Policy (~12 minutes) - Jeffrey Drope, Johns Hopkins University (<i>participating virtually</i>) Communicating About Alcohol and Cancer Risk: Challenges, Opportunities, and a Way Forward (~12 minutes) - Jennifer Hay, Memorial Sloan Kettering Cancer Center

	Communication and Awareness (~12 minutes) - William Klein, National Cancer Institute (<i>participating virtually</i>) Impact of Marketing on the Youth (~12 minutes) - Raimee Eck, Johns Hopkins Bloomberg School of Public Health and Sonrisa Solutions (<i>participating virtually</i>) A Cancer Center's Perspective (~12 minutes) - Mark Evers, University of Kentucky Markey Cancer Center Panel Discussion (~50 minutes)
3:20 pm	Break (15 minutes)
3:35 pm	Session 4: Evidence-Based Interventions for Tobacco Cessation and to Help Patients Reduce Alcohol Use (~1 hour, 55 minutes) <i>Co-Moderators:</i> Roy Jensen, University of Kansas Cancer Center Roy Herbst, Yale University <i>Session Objective:</i> To examine effective approaches to reduce tobacco use and discuss how these strategies can be applied to develop and implement interventions to reduce heavy alcohol use. Tailored Email Messages to Help People Quit Smoking: Can It Be Replicated to Help People Quit Heavy Drinking? (~10 minutes) J. Lee Westmaas, American Cancer Society Quitlines (~10 minutes) - Shu-Hong Zhu, University of California, San Diego Lessons Learned in Tobacco Control in Youth and Young Adults (~10 minutes) - Pamela Ling, University of California, San Francisco Novel Smoking and Vaping Cessation Approaches (~10 minutes) - Benjamin Toll, Medical University of South Carolina Pharmacologic Interventions (~10 minutes) - Babalola Faseru, University of Kansas Medical Center Community Tailored Interventions (~20 minutes) - Francisco Cartujano-Barrera, University of Rochester Medical Center - Ayana Jordan, New York University Grossman School of Medicine (<i>participating virtually</i>) Panel Discussion (~45 minutes)
5:30 pm	Adjourn and Reception

**TUESDAY, MARCH 18, 2025
EASTERN TIME ZONE**

8:00 am	Breakfast and Registration (30 minutes)
8:30 am	Welcome and Introductory Remarks (5 minutes) S. Gail Eckhardt, Planning committee co-chair
8:35 am	Keynote Presentation: Addressing Modifiable Risk Factors Through Public Health Strategies: Lessons from Tobacco (~20 minutes) Brian King, U.S. Food and Drug Administration
8:55 am	Session 5: Addressing Gaps in Evidence, Practice, and Policy for Tobacco and Alcohol Use (~1 hour, 30 minutes) <i>Co-Moderators:</i> <i>Chanita Hughes-Halbert, University of Southern California</i> <i>Robert Winn, Massey Comprehensive Cancer Center, Virginia Commonwealth University</i> <i>Session Objective:</i> Discuss gaps in evidence, practice, and policy for tobacco and heavy alcohol use and examine potential strategies to address the gaps. Addressing Stigmatization and Perception Bias (~10 minutes) - Lisa Carter-Bawa, Cancer Prevention Precision Control Institute Real World Experience of Alcohol and Tobacco in a National Health System (~10 minutes) - Amy Justice, Yale University; Veterans Affairs Connecticut Healthcare System Youth Focused Policy: Differences between Tobacco and Alcohol (~10 minutes) - Adam Leventhal, University of Southern California (<i>participating virtually</i>) Addressing Gaps of Evidence on Moderate Alcohol Consumption and Health (~10 minutes) - Ned Calonge, Colorado School of Public Health Addressing the Gaps in Interventions to Prevent Tobacco Use to Lower Cancer Risk (~10 minutes) - Kolawole Okuyemi, Indiana University School of Medicine Evidence Gaps in Economic Research in Connection with Alcohol Taxation (~10 minutes) - Nigar Nargis, American Cancer Society Panel Discussion (~30 minutes)
10:25 am	Break (15 minutes)
10:40 am	Session 6: Concluding Discussion and Next Steps (50 minutes) <i>Co-Moderators:</i> <i>Gail Eckhardt, Baylor College of Medicine</i> <i>Roy Herbst, Yale University</i> Session co-moderators reconvene to summarize key observations and opportunities Session 1: Elena Martínez and S. Gail Eckhardt Session 2: Nigar Nargis and Gwen Darien Session 3: S. Gail Eckhardt and Roy Herbst Session 4: Roy Jensen and Roy Herbst Session 5: Chanita Hughes-Halbert and Robert Winn
11:30 am	Adjourn

Sponsors of the National Cancer Policy Forum

Centers for Disease Control and Prevention

National Institutes of Health/National Cancer Institute

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Cancer Care Centers

Cancer Center at Illinois

Flatiron Health

Merck

National Comprehensive Cancer Network

Patient Advocate Foundation

Novartis Oncology

Oncology Nursing Society

Partners In Health

Pfizer Inc

We are grateful for the support of our sponsors, which is crucial to the work of the Forum.

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes: A Workshop

March 17-18, 2025

Planning Committee Roster

S. Gail Eckhardt, MD, FASCO (Co-Chair)

Associate Dean of Experimental Therapeutics
Baylor College of Medicine
Associate Director of Translational Research
Dan L. Duncan Comprehensive Cancer Center

Roy S. Herbst, MD, PhD (Co-Chair)

Ensign Professor of Medicine
Chief of Medical Oncology and Hematology
Deputy Director
Yale Cancer Center and Smilow
Cancer Hospital
Assistant Dean for Translational Research
Yale School of Medicine

Gwen Darien, BA

Executive Vice President
Patient Advocacy and Engagement
Patient Advocate Foundation

Scarlett Lin Gomez, PhD, MPH

Professor
Department of Epidemiology and Biostatistics
Co-Leader
Cancer Control Program
Helen Diller Family Comprehensive
Cancer Center
University of California, San Francisco

Chanita Hughes-Halbert, PhD

Vice Chair for Research and Professor
Department of Population and Public Health Sciences
Dr. Arthur and Priscilla Ulene Chair in
Women's Cancer
Keck School of Medicine
Associate Director for Cancer Equity
Norris Comprehensive Cancer Center
University of Southern California

Farhad Islami, MD, PhD

Senior Scientific Director
Cancer Disparity Research
Department of Surveillance &
Health Equity Science
American Cancer Society

Roy A. Jensen, MD

Vice Chancellor and Director
University of Kansas Cancer Center
William R. Jewell, M.D. Distinguished Kansas
Masonic Professor of Cancer Research
Director
Kansas Masonic Cancer Research Institute
Professor
Pathology and Laboratory Medicine
University of Kansas Medical Center
Past President
Association of American Cancer Institutes

Elena Martínez, PhD, MPH

Sam M. Walton Endowed Chair for
Cancer Research
Professor
Herbert Wertheim School of Public Health and
Human Longevity Science
Associate Director
Population Sciences, Disparities, and
Community Engagement
Moores Cancer Center
University of California, San Diego

Nigar Nargis, PhD

Senior Scientific Director
Tobacco Control Research
Department of Surveillance & Health Equity Science
American Cancer Society

Lisa C. Richardson, MD, MPH

Director
Division of Cancer Prevention and Control
Centers for Disease Control and Prevention

Deidra Roach, MD

Program Director
Treatment, Health Services, and
Recovery Branch
Division of Treatment and Recovery
National Institute on Alcohol Abuse and Alcoholism

Katrina F. Trivers, PhD, MSPH

Associate Director for Science
Division of Cancer Prevention and Control
National Center for Chronic Disease Prevention
and Health Promotion,
Centers for Disease Control and Prevention

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes: A Workshop

March 17-18, 2025

Speaker, Panelist, and Moderator Roster

Jessica Barrington-Trimis, PhD

Associate Professor of Population and Public Health
Sciences
Director
Real-world Evaluation in Behavioral Epidemiology Lab
(REBEL) Research
USC Institute for Addiction Science (IAS)
University of Southern California

David Berrigan, PhD, MPH

Program Director
Behavioral Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute

Melissa Buffalo, MS

Chief Executive Officer
American Indian Cancer Foundation
(Meskwaki and Dakota)

Ned Calonge, MD, MPH

Associate Dean of Public Health Practice
Colorado School of Public Health

Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN

Director
Cancer Prevention Precision Control Institute
Center for Discovery & Innovation
Hackensack Meridian Health
Deputy Associate Director
Community Outreach & Engagement
Georgetown Lombardi Comprehensive Cancer Center
Director
Cancer Community Outreach & Engagement
John Theurer Cancer Center at
Hackensack Meridian Health

Francisco Cartujano-Barrera, MD

Assistant Professor
Department of Public Health Sciences
Center for Community Health and Prevention
Assistant Director
Office of Community Outreach and Engagement
Wilmot Cancer Institute
Director
Wilmot Tobacco Cessation Program
University of Rochester Medical Center

Gwen Darien, BA

Executive Vice President
Patient Advocacy and Engagement
Patient Advocate Foundation

Jeffrey Drope, PhD

Research Professor
Director
Economics for Health
Bloomberg School of Public Health
Johns Hopkins University

Raimee H. Eck, PhD, MPH, MPAS, CPH

Chair
Maryland Alcohol, Tobacco & Cannabis Network
Associate
Health, Behavior & Society Department
Johns Hopkins Bloomberg School of Public Health
Founder and Principal
Sonrisa Solutions

S. Gail Eckhardt, MD, FASCO

Associate Dean of Experimental Therapeutics
Baylor College of Medicine
Associate Director of Translational Research
Dan L. Duncan Comprehensive Cancer Center

B. Mark Evers, MD

Director
Markey Cancer Center
Associate Vice President for Oncology Research and
Strategic Development
Professor
Department of Surgery
Markey Cancer Foundation Endowed Chair
University of Kentucky

Babalola Faseru, MBChB, MPH, CPH, SRNT Fellow

Department of Population Health
Professor of Population Health, Family Medicine, and
Community Health
University of Kansas Medical Center
Cancer Prevention and Control Program
University of Kansas Cancer Center
Consultant Medical Epidemiologist
Bureau of Health Promotion
Kansas Department of Health and Environment

Geoffrey T. Fong, OC, PhD, FRSC, FCAHS

University Professor of Psychology and
Public Health Sciences
University of Waterloo
Senior Investigator
Ontario Institute for Cancer Research

Neal Freedman, PhD, MPH

Branch Chief
Tobacco Control Research Branch
Division of Cancer Control and
Population Sciences (DCCPS)
National Cancer Institute

Jo Freudenheim, PhD, MS, RD, FACE, FASN

SUNY Distinguished Professor
Department of Epidemiology and Environmental Health
School of Public Health and Health Professions
University at Buffalo

Ella Greene-Moton

Immediate-Past President
American Public Health Association

Jennifer L. Hay, PhD

Member and Attending Psychologist
Co-Director
Genomics, Risk & Health Decision Making Laboratory
Director
T32 Research Fellowship in Psycho-Oncology
Department of Psychiatry & Behavioral Sciences
Memorial Sloan Kettering Cancer Center

Stephen Hecht, PhD

Wallin Professor of Cancer Prevention
American Cancer Society Professor
American Chemical Society Fellow
Masonic Cancer Center
Cancer and Cardiovascular Research
University of Minnesota

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine
Chief of Medical Oncology and Hematology
Deputy Director
Yale Cancer Center and Smilow
Cancer Hospital
Assistant Dean for Translational Research
Yale School of Medicine

Chanita Hughes-Halbert, PhD

Vice Chair for Research and Professor
Department of Population and Public Health Sciences
Dr. Arthur and Priscilla Ulene Chair in
Women's Cancer
Keck School of Medicine
Associate Director for Cancer Equity
Norris Comprehensive Cancer Center
University of Southern California

Farhad Islami, MD, PhD

Senior Scientific Director
Cancer Disparity Research
Department of Surveillance & Health Equity Science
American Cancer Society

Roy A. Jensen, MD

Vice Chancellor and Director
University of Kansas Cancer Center
William R. Jewell, M.D. Distinguished Kansas
Masonic Professor of Cancer Research
Director
Kansas Masonic Cancer Research Institute
Professor
Pathology and Laboratory Medicine
University of Kansas Medical Center
Past President
Association of American Cancer Institutes

Ayana Jordan, MD, PhD

Associate Professor
Department of Population Health
Barbara Wilson Associate Professor of Psychiatry
Department of Psychiatry
New York University Grossman School of Medicine

Amy C. Justice, MD, PhD

CNH Long Professor of Medicine and Public Health
Yale University
Staff Physician
Veterans Affairs Connecticut Healthcare System

Brian A. King, PhD, MPH

Director
Center for Tobacco Products
U.S. Food and Drug Administration

William E. Klein, PhD

Associate Director
Behavioral Research
Division of Cancer Control and Population Sciences
National Cancer Institute

Adam Leventhal, PhD

Director
USC Institute for Addiction Science
Professor of Population and Public Health Sciences and
Psychology
Keck School of Medicine
University of Southern California

Pamela Ling, MD, MPH

Professor of Medicine
Director
Center for Tobacco Control Research and Education
University of California, San Francisco

Elena Martínez, PhD, MPH

Sam M. Walton Endowed Chair for
Cancer Research
Professor
Herbert Wertheim School of Public Health and
Human Longevity Science
Associate Director
Population Sciences, Disparities, and
Community Engagement
Moore's Cancer Center
University of California, San Diego

Nigar Nargis, PhD

Senior Scientific Director
Tobacco Control Research
Department of Surveillance & Health Equity Science
American Cancer Society

Kolawole Okuyemi, MD, MPH

Associate Dean for Health Equity Research and
Implementation
Chair, Department of Family Medicine
OneAmerica Foundation Professor of Preventative
Health Medicine
Professor of Family Medicine
Associate Dean for Health Equity Research and
Implementation
Indiana University School of Medicine

Kurt M. Ribisl, PhD

Jo Anne Earp Distinguished Professor and Chair
Department of Health Behavior
University of North Carolina Gillings School of
Global Public Health
Cancer Prevention and Control Program Leader
UNC Lineberger Comprehensive Cancer Center

Harriet Rungay, PhD

Epidemiologist
Cancer Surveillance Branch
International Agency for Research on Cancer
World Health Organization

Benjamin A. Toll, PhD

Professor of Public Health Sciences and Psychiatry
Vice Chair of Research
Public Health Sciences
Associate Director
Education and Training
Co-Director
Lung Cancer Screening Program
Director
MUSC Health Tobacco Treatment Program
Medical University of South Carolina

Graham Warren MD, PhD, FASCO

Professor and Mary M. Gilbreth Endowed Chair of
Clinical Oncology
Vice Chairman for Research in Radiation Oncology
Department of Radiation Oncology
Department of Cell and Molecular Pharmacology and
Experimental Therapeutics
Hollings Cancer Center
Medical University of South Carolina

J. Lee Westmaas, PhD

Scientific Director
Tobacco Control Research
American Cancer Society

Robert A. Winn, MD

Director
Massey Comprehensive Cancer Center
Senior Associate Dean for Cancer Innovation
Professor of Pulmonary Disease and
Critical Care Medicine
Lipman Chair in Oncology
Virginia Commonwealth University
School of Medicine
President
Association of American Cancer Institutes

Hang Zhou, PhD

Assistant Professor of Psychiatry and Biomedical
Informatics & Data Science
Yale School of Medicine

Shu-Hong Zhu, PhD

Professor of Public Health
Herbert Wertheim School of Public Health
Director
Center for Research in Tobacco Control
University of California, San Diego
Principal Investigator
Kick It California, Asian Smoker's Quitline, Youth
Vaping Alternative Program Education (YVAPE)

**Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes:
A Workshop**
March 17-18, 2025

Speaker, Panelist, Moderator, and Planning Committee Biosketches



Jessica Barrington-Trimis, PhD
University of Southern California

Dr. Barrington-Trimis is an epidemiologist and Associate Professor of Population and Public Health Sciences at the University of Southern California. She directs the USC REBEL Research team and is a faculty member in the USC Institute for Addiction Science and the USC Norris Comprehensive Cancer Center. Dr. Barrington-Trimis' research focuses on investigation of the rapidly changing tobacco and alternative tobacco landscape. Her work aims to identify intraindividual psychological, behavioral, and social processes associated with nicotine use in adolescence and early adulthood, and to elucidate the behavioral consequences (e.g., transition to more harmful patterns of substance use) of varying patterns of nicotine product use in adolescence, with the goal of informing regulatory efforts to protect adolescents and young adults.



David Berrigan, PhD, MPH
National Cancer Institute

David Berrigan, Ph.D., M.P.H., has been a Program Officer in the Division of Cancer Control and Population Sciences since 2003. He has a PhD from the University of Utah and an MPH from UC Berkeley. His programmatic and research efforts focus on how the built and natural environments influence physical activity and obesity, on better measurement of behavior and context, and on alcohol as a target for cancer prevention and control. Dr. Berrigan is strongly committed to research aimed at health for all via environments and institutions that support healthy choices, preventive services, and health care regardless of demographic or economic circumstances.



Melissa Buffalo, MS
American Indian Cancer Foundation

Ms. Buffalo is an enrolled member of the Meskwaki Nation in Iowa, and Dakota from the Crow Creek and Lower Brule Sioux Tribes. She received her undergraduate degree in child psychology from the University of Minnesota – Twin Cities and earned an MS in Human Development from South Dakota State University. Melissa has over 15 years of experience working in the public health sector in a variety of different roles, she brings a wealth of knowledge to AICAF. As the CEO, Melissa is committed to working with and for Tribal Nations, and urban and rural tribal communities with opportunities to heal; emotionally, historically, spiritually, and physically from the inequities of cancer. Her responsibilities as the CEO of the American Indian Cancer Foundation include the overall direction and implementation of a strategic vision to improve Indigenous cancer outcomes nationally.



Ned Calonge, MD, MPH
Colorado School of Public Health

Ned Calonge, MD, MPH, is a professor of Epidemiology and the Associate Dean for Public Health Practice at the Colorado School of Public Health, and is the Chief Medical Officer for the Colorado Department of Public Health and Environment. He is an associate professor of Family Medicine at the University of Colorado School of Medicine. Nationally, Dr. Calonge chairs HRSA's Advisory Committee on Heritable Disorders of Newborns and Children. He is past chair of the NASEM Board on Population Health and Public Health Practice, past chair of CDC's Community Services Task Force, past chair of the U.S. Preventive Services Task Force and past chair of CDC's Evaluating Genomic Applications in Practice and Prevention Working Group. He has served on and chaired several NASEM consensus studies including studies on health equity, genetic testing in medicine, safety

and quality of abortion services, evidence-based public health emergency preparedness and response, PFAS testing, exposure reduction and clinical follow up, the VA Presumptive Decision Process, and most recently, the study of alcohol and health. Dr Calonge received his MD from the University of Colorado, his MPH from the University of Washington, and is board certified in Preventive Medicine.



Lisa Carter-Bawa, PhD, MPH, APRN, ANP-C, FAAN
Cancer Prevention Precision Control Institute

Dr. Lisa Carter-Bawa (formerly Carter Harris) is a behavioral scientist and nurse practitioner. She is the Director of the Cancer Prevention Precision Control Institute at the Center for Discovery & Innovation at Hackensack Meridian Health in New Jersey and the Director of Community Outreach & Engagement at the John Theurer Cancer Center. She is the Deputy Associate Director of Community Outreach & Engagement at Georgetown Lombardi Comprehensive Cancer Center. Dr. Carter-Bawa's research focuses on the many factors that influence the decision-making process in lung cancer screening decisions as well as actual screening behavior. She has a particular passion for understanding how stigma influences the decision to screen, or not, for lung cancer. She has co-designed and developed tailored interventions that support lung screening awareness, decision-making and screening

uptake with particular attention to addressing health equity in lung cancer screening. Her research has been funded by NCI, the American Lung Association, and the New Jersey Commission on Cancer. She is a Fellow of the American Academy of Nursing and co-leads the American Academy of Nursing Health Expert Tobacco Control Subcommittee. She is also a Fellow of the Society of Behavioral Medicine. Dr. Carter-Bawa is Chair of the Stigma & Nihilism Task Group of the ACS NLCRT.



Francisco Cartujano-Barrera, MD
University of Rochester Medical Center

Dr. Francisco Cartujano-Barrera (he/él) is an Assistant Professor of Public Health Sciences and Community Health and Prevention at the University of Rochester Medical Center (URMC). Moreover, he is an Assistant Director of the Office of Community Outreach and Engagement at Wilmot Cancer Institute, part of URMC. Furthermore, Dr. Cartujano-Barrera is the Director of the Wilmot Tobacco Cessation Program.



Gwen Darien, BA
Patient Advocate Foundation

Gwen Darien is a longtime patient advocate who has played leadership roles in some of the country's preeminent nonprofit organizations. As executive vice president for patient advocacy, engagement and education, Gwen leads programs that link Patient Advocate Foundation's direct patient service programs to PAF patient education and system change initiatives, with the goal of improving access to affordable, equitable quality health care.

As a three-time cancer survivor herself, Darien came into cancer advocacy expressly to change the experiences and outcomes for the patients who came after her and to change the public dialogue about cancer and other life-threatening illnesses. With these goals in mind, in 2005 she started the first stand-alone advocacy entity in a professional cancer

research organization at the American Association for Cancer Research. At AACR, she launched *CR* magazine – a magazine for people with cancer and those who care for them. Later, she served as the executive vice president of programs and services at the Cancer Support Community. In each role, Darien championed placing patients at the center of health system change, whether it is for research, public policy or direct services.

Gwen Darien serves on a wide range of program committees and workshop faculties. Darien serves on the Board of Trustees of the USP and is a member of the National Cancer Policy Forum. She co-chairs the Individual and Community health goals working group of the National Academy of Medicine's Commission on Investment Imperatives for a Healthy Nation. She is the past Chair of PCORI's Patient Engagement Advisory Panel and founding Chair of Community Engagement in Genomics Working Group of the National Human Genome Research. Gwen also writes about her experiences as an advocate and cancer survivor. A recent piece, *Transformation: My Experience as a Patient and an Advocate in Three Chapters* appeared in the National Academy of Medicine Perspectives.



Jeffrey Drope, PhD
Johns Hopkins University

Dr. Jeffrey Drope is a Research Professor at the Johns Hopkins Bloomberg School of Public Health as well as the director of the Economics for Health research project. Jeff's work focuses on the nexus of major public health challenges (including tobacco control, nutrition, physical activity, alcohol use, food security, etc.) and economic policymaking, especially taxation, trade and investment. His work seeks to integrate these areas in proactive ways that engender both improved public health outcomes and economic prosperity. His tobacco and alcohol control work focuses particularly on taxation, illicit trade, and these products' economic costs. For tobacco, his research also explores the science and regulation of novel products (e.g., electronic cigarettes) and the economics of tobacco farming. He is the author/editor of three books and more than 200 research articles, chapters and reports on the political economy of non-communicable disease.

Together with colleagues, he works globally to provide technical support and counsel on these issues to governments, intergovernmental organizations, research institutions and civil society organizations. From 2012 to 2020, Jeff was Scientific Vice President of Economic and Health Policy Research at the American Cancer Society.



Raimee H. Eck, PhD, MPH, MPAS, CPH

Johns Hopkins Bloomberg School of Public Health; Sonrisa Solutions

Raimee H. Eck, PhD, MPH, MPAS, CPH has over 20 years of clinical and public health training and experience, focusing on the epidemiology of alcohol use and harm, environmental interventions to reduce alcohol-related harm, and translating research into effective policy. She also completed a Cancer Research Training Award Fellowship at the National Cancer Institute where she studied the role of alcohol in the development of cancer, the co-use of alcohol with other behavioral risk factors (e.g., tobacco), and points of intervention along the cancer control continuum. Raimee is a Past President of the Maryland Public Health Association, where she currently leads the statewide Alcohol, Tobacco & Cannabis Network. She is the founder and principal of Sonrisa Solutions, providing expertise on topics such as alcohol, tobacco, and cannabis epidemiology, regulation, and enforcement; public health policy translation; and advocacy in the form of research reports, workshops, and webinars.

Raimee received her Bachelor of Health Science and Master of Physician Assistant Studies from Duquesne University in Pittsburgh, PA and her MPH and PhD from the Johns Hopkins Bloomberg School of Public Health (JHSPH). She also teaches Media Advocacy in the Department of Health, Behavior & Society at JHSPH.




S. Gail Eckhardt, MD, FASCO

Baylor College of Medicine

S. Gail Eckhardt is a tenured Professor, Associate Dean of Experimental Therapeutics and holds the Albert and Margaret Alkek Foundation Chair at Baylor College of Medicine; she is also the Associate Director of Translational Research at the Dan L Duncan Comprehensive Cancer Center. Dr. Eckhardt has served on numerous committees and study sections, including the ASCO Molecular Oncology Task Force, the ASCO Board of Directors, the FDA Oncology Drugs Advisory Committee, and the National Cancer Institute (NCI) Cancer Centers Study Section. She serves on 10 external advisory boards of NCI-designated cancer centers, was a lead mentor in ASCO's Leadership Development Program, past member of the Board of Directors of the Association of American Cancer Institutes (AACI) and previous Chair of the Cancer

Prevention and Research Institute of Texas' Clinical Trials Advisory Committee. She is a current member of the National Academies of Science, Engineering, and Medicine's Cancer Policy Forum and the Scientific Advisory Committee of SU2C. Dr. Eckhardt was awarded ASCO's 2022 Women Who Conquer Cancer Mentorship Award.

Dr. Eckhardt has been Principal Investigator on grants involving early clinical trials and colorectal cancer research, has conducted numerous early phase clinical trials, and has published over 200 manuscripts. Her area of interest is in the preclinical and early clinical development of combinations of molecularly targeted compounds. Dr. Eckhardt earned her undergraduate degree in chemistry from Stephen F. Austin State University and her medical degree from the University of Texas Medical Branch in Galveston. She conducted her internship and residency in Internal Medicine at the University of Virginia Medical School, followed by a post-doctoral research fellowship in Experimental and Molecular Medicine at Scripps Research Institute in La Jolla, California, and a fellowship in Medical Oncology at the University of California San Diego.



B. Mark Evers, MD

University of Kentucky Markey Cancer Center

Dr. Evers is an accomplished surgical oncologist, cancer researcher, educator and administrator. He was recruited to the University of Kentucky (UK) in 2009 as Director of the UK Markey Cancer Center (MCC), Physician-in-chief of the Oncology Service Line, and Associate Vice-President for Oncology Research and Strategic Development. Under his leadership, the MCC achieved NCI designation in 2013, successfully competed for renewal of its Cancer Center Support Grant (P30) in 2018, and achieved Comprehensive status with its recent renewal in 2023. Prior to his recruitment to UK, Dr. Evers was the Robertson-Poth Distinguished Chair in General Surgery and Director of the University of Texas Medical Branch (UTMB) Cancer Center.

Dr. Evers has been continuously funded by the NIH for over 30 years and has published more than 450 peer-reviewed publications, book chapters and reviews. Throughout his career, he has received more than 30 awards including the Flance-Karl research award from the American Surgical Association (ASA). He is an elected member of the National Academy of Medicine (NAM), the Association of American Physicians (AAP), and the American Society for Clinical Investigation (ASCI). In addition, he has held leadership positions in a number of surgical societies including past President of the Society for University Surgeons, past President of the Southern Surgical Association and past Treasurer of the ASA.



Babalola Faseru, MBChB, MPH, CPH, SRNT Fellow

University of Kansas Medical Center

Dr. Babalola Faseru is a Professor of Population Health, Family Medicine, and Community Health at the University of Kansas Medical Center (KUMC) and a Consultant Medical Epidemiologist at the Kansas Department of Health and Environment (KDHE). He earned his Medical Degree from Obafemi Awolowo University, Nigeria, and a Master of Public Health from the University of Kuopio (now the University of Eastern Finland), supported by a Cancer Research Fellowship from the WHO International Agency for Research on Cancer in Lyon, France.

At KUMC, Dr. Faseru completed Postdoctoral Fellowship in Tobacco Research and an NIH K30 Fellowship in Clinical Epidemiology. As Professor and Director of the University of Kansas Tobacco Treatment Education Program, he has trained over 500 Tobacco

Treatment Specialists and received multiple teaching awards from the University of Kansas School of Medicine.

A Fellow of the Society for Research on Nicotine and Tobacco (SRNT), Dr. Faseru has been honored with the Murray Goldstein Commemorative Lectureship Award from the American Osteopathic College of Occupational and Preventive Medicine and the International Association for Study on Lung Cancer Lectureship Award in Tobacco Control and Smoking Cessation.

As a Full Member of the University of Kansas Cancer Center, his research focuses on cancer prevention, tobacco dependence, and smoking cessation, with an emphasis on reducing tobacco-related health disparities. He has led and collaborated on NIH-funded clinical trials and state and private grants totaling over \$24 million. His work, published in high-impact journals like JAMA, JNCI, and Addiction, has been cited in the 2020 and 2024 Surgeon General's reports on Smoking Cessation and Eliminating Tobacco-Related Disease and Death: Addressing Disparities.

Dr. Faseru holds leadership roles in organizations such as the Council for Tobacco Treatment Training Programs (CTTTP), the Society for Research on Nicotine and Tobacco (SRNT), and the International Association for the Study of Lung Cancer (IASLC). He serves on NIH study sections, journal editorial boards, and is the Deputy Editor of the Substance Use and Addiction journal.

An advocate for health equity, Dr. Faseru has mentored over 150 students and early-career professionals, many from underrepresented backgrounds, and remains a leading voice in tobacco control and public health research both nationally and internationally.



Geoffrey T. Fong, OC, PhD, FRSC, FCAHS
University of Waterloo

Geoffrey T. Fong, OC, PhD, FRSC, FCAHS is University Professor of Psychology and Public Health Sciences at the University of Waterloo, and Senior Investigator at the Ontario Institute for Cancer Research. Dr. Fong is the Founder and Chief Principal Investigator of the International Tobacco Control Policy Evaluation (ITC) Project, a consortium of 150 researchers across 31 countries, covering over half of the world's population; in each country, longitudinal cohort surveys of tobacco users have been conducted (180 survey waves since 2002), with findings published in over 800 scientific articles. Dr. Fong has been named to the Clarivate Analytics List of Highly Cited Researchers in 9 of the past 10 years. A primary objective of the ITC Project is to evaluate policies of the global tobacco control treaty, the WHO Framework Convention on Tobacco Control (FCTC), including graphic health warnings, smoke-free laws, price/tax policies, tobacco marketing restrictions, and cessation support. For the past decade, e-cigarettes and other new nicotine products has been another ITC focus.

Dr. Fong has contributed to many landmark reports, including those of the International Agency for Research on Cancer, US Surgeon General, WHO, US National Academy of Sciences, and UK Royal College of Physicians. He was a contributing author to the Institute of Medicine's 2015 report, *Understanding the U.S. Illicit Tobacco Market: Characteristics, Policy Context, and Lessons from International Experiences*, and was one of the three Scientific Editors of the 2016 WHO/US National Cancer Institute Monograph, *The Economics of Tobacco and Tobacco Control*.

Dr. Fong was a member/Technical Coordinator of the WHO FCTC Impact Assessment Expert Group, which conducted the official evaluation of the FCTC in its first decade (2005-15); Dr. Fong designed the multi-method evaluation program, the results of which were presented to the FCTC Conference of the Parties. Dr. Fong is currently a Vice-Chair for the WHO FCTC Expert Group on Article 2.1 (forward-looking measures). Dr. Fong has been an expert consultant for WHO, FCTC Secretariat, and many countries including the US, Canada, Australia, Brazil, United Kingdom, Malaysia, and Singapore. He was an expert for Australia and Uruguay in successful defenses of their policies against the tobacco industry's legal challenges via trade treaties (Australia defending its plain packaging law at the World Trade Organization and Uruguay defending its labeling and brand presentation policies at a bilateral investment treaty tribunal). Dr. Fong is also a member of the Scientific Leadership Team for the US FDA/NIDA Population Assessment of Tobacco and Health (PATH) Study. Dr. Fong's recognitions include the global Luther Terry Award for Outstanding Research Contribution, WHO No Tobacco Day Award, Health Research Foundation Medal of Honour, Top Canadian Achievement in Health Research, AAPOR Policy Impact Award, Society for Research on Nicotine and Tobacco John Slade Award, the Canadian Cancer Society O. Harold Warwick Prize for outstanding achievement in cancer control research, and the Canadian Governor General's Innovation Award. In 2021, Dr. Fong was appointed as an Officer of the Order of Canada, and in 2025, Dr. Fong will be inducted into the Canadian Medical Hall of Fame.



Neal Freedman, PhD, MPH

National Cancer Institute

Neal D. Freedman, PhD, MPH, is chief of the Tobacco Control Research Branch (TCRB) in the Division of Cancer Control and Population Sciences at the National Cancer Institute (NCI). In 1998, Dr. Freedman received his bachelor's degree from Brown University with dual concentrations in biochemistry and Colonial American history. In 2004, he received a PhD in biomedical sciences from the University of California San Francisco, where he worked with Dr. Keith Yamamoto on the biology of nuclear receptors. Then, he became an NCI Cancer Prevention Fellow and in 2005 received an MPH in quantitative methods from the Harvard T.H. Chan School of Public Health. Following a postdoctoral fellowship in NCI's Division of Cancer Epidemiology and Genetics, he became a tenure track investigator in 2009 and received scientific tenure in 2015. In 2023, he joined TCRB. He is an elected member of the American Epidemiological Society.

Dr. Freedman's scientific interests include common, potentially modifiable, exposures of public health significance, including tobacco, alcohol, opioids, and cannabis. He tracks usage trends, examines disease risks and burden, investigates underlying mechanisms, and develops new resources. He is interested in the contemporary disease and mortality risks of established and emerging tobacco products and usage patterns, including non-daily and dual- and poly-use. He has conducted mechanistic studies examining physiologic and molecular effects and surveillance studies examining usage patterns. Additionally, he has used tools of descriptive epidemiology to track trends in cancer and other major causes of death in the United States.



Jo Freudenheim, PhD, MS, RD, FACE, FASN

University at Buffalo

Jo Freudenheim, PhD, MS, RD is a SUNY Distinguished Professor in the Department of Epidemiology and Environmental Health at the University at Buffalo in the School of Public Health and Health Professions. Her research has focused on breast cancer epidemiology, seeking to use epidemiologic tools to understand carcinogenesis at the population, individual, tissue and molecular levels to better prevent and control the disease. With a long research focus on diet and alcohol with regard to cancer, she was among the first to examine the interaction of folate with alcohol in relation to cancer risk. Recent work has focused on factors related to all-cause and breast cancer specific mortality following a breast cancer diagnosis, including molecular differences in breast tissues as indicators of the carcinogenic process. She is a fellow of the American Society for Nutrition and the American College of Epidemiology and received the Abraham Lilienfeld Award from the American Public Health Association Epidemiology Section. Freudenheim received her PhD

in nutritional sciences and MS in preventive medicine from the University of Wisconsin-Madison and did postdoctoral training at the University at Buffalo.



Scarlett Lin Gomez, PhD, MPH

University of California, San Francisco

Scarlett Lin Gomez is Professor and Vice Chair for Faculty Development in the Department of Epidemiology and Biostatistics and Co-Leader of the Cancer Control Program of the Helen Diller Family Comprehensive Cancer Center, at the University of California, San Francisco. She is Director of the Greater Bay Area Cancer Registry, a participant in the NCI SEER (Surveillance, Epidemiology, End Results) program and the California Cancer Registry. Her research focuses primarily on cancer health disparities and aims to understand the multilevel drivers, particularly the structural and social determinants of health, of those disparities. With over 300 publications, she has led cancer surveillance research to document disparities in population groups defined by detailed race, ethnicity, socioeconomic status, nativity, and neighborhood factors. In particular, she has provided

empirical evidence of heterogeneity and hidden disparities in cancer patterns and trends for disaggregated Asian

American, Native Hawaiian, and Pacific Islander groups, and has been a voice for disaggregation and advocate for more research. She has led efforts to develop databases to characterize structural and social drivers of health, and has contributed to commentaries and scientific reports, including the AACR Cancer Health Disparities reports, to understand multi-level contributors to outcomes across the cancer continuum. In recognition of these efforts and impacts, she has been honored with several awards, including the ASPO Joseph F. Fraumeni, Jr. Distinguished Achievement Award in 2023, the Christopher N. H. Jenkins Cancer Control Award for community-oriented cancer prevention and control efforts in Asian Americans and Pacific Islanders, the AACR Distinguished Lecture in Cancer Health Disparities Award, and the UCSF Felix Feng Prostate Cancer Program Keynote Lectureship.



Ella Greene-Moton
American Public Health Association

Ella has an extensive background in public health advocacy, public health policy, Community-Based Participatory Research (CBPR), and programming, spanning over the past forty plus (40+) years in the City of Flint and surrounding areas. In addition, specific efforts in public health Ethics have focused on providing awareness at the community level, developing and elevating the community voice and advocating for community inclusiveness at the State and National Levels. Her areas of expertise include facilitating community/academic/practice partnership building and sustainability; developing, managing, and evaluating community-based projects; and training programs for graduate students, community members, as well as middle and high school students partnering with community-based organizations, schools, and public health agencies.

Ella served from 2006-2019 as a Community Education Coordinator and "Bridge" at the Center for Public Health and Community Genomics, at the School of Public Health – University of Michigan – Ann Arbor, and currently serves as the Community Based Organization Partners (CBOP) Community Ethics Review Board (CERB) Administrator, based in Flint, MI.

Over the years, she has served as an Independent Community-Academic Consultant working with several local and national academic institutions, engaged in Community Based Participatory Research (CBPR) with their local communities, including: the Michigan Institute for Clinical & Health Research (MICH) Community Engagement Steering Committee; the Morehouse School of Medicine Prevention Research Center's External Advisory Committee (EAC); the Robert Wood Johnson Foundation (RWJF) Clinical Scholars National Advisory Committee; the Arkansas Center for Health Disparities (ARCHD) Steering Committee; the National Human Genome Research Institute (NHGRI) Community Engagement Genomics Working Group; the National Academy of Medicine (NAM) Leadership Consortium; the Engage for Equity (E2) Think Tank; the Measurement Approaches to Partnership Success (MAPS) Expert Panel, and the Flint NAACP Executive Board.

Ella also serves as the immediate past Michigan Affiliate Representative for the Governing Council (ARGC); a member of the Michigan Public Health Association; a member of the Community Based Public Health (CBPH) Caucus; a member of the National Community Based Organization Network (NCBON), all affiliated with the American Public Health (APHA).




Jennifer L. Hay, PhD

Memorial Sloan Kettering Cancer Center

Dr. Jennifer Hay is an Attending Psychologist in the Department of Psychiatry & Behavioral Sciences at Memorial Sloan Kettering Cancer Center (MSK), and Professor of Psychology in Psychiatry in the Department of Psychiatry at Weill Cornell Medical College. She serves as Co-Director of the Genomics, Risk, and Health Decision-Making Laboratory, and Director of MSK Psycho-Oncology Research Training Program, supported by an NIH T32 training grant. Her NIH and foundation-funded research program focuses on optimizing the public health benefit of novel basic science, genomics, and epidemiological findings in cancer by mobilizing cancer risk perceptions and protective behavior. Her recent work centers around addressing the challenge of high population uncertainty about cancer risk, using genetic information to provide skin cancer risk feedback in precision prevention interventions, and understanding the role of motivational and cultural

processes in public appreciation of the cancer harms of alcohol consumption.



Stephen Hecht, PhD

University of Minnesota

Stephen S. Hecht received a B.S. from Duke University (1964) and a Ph.D. from MIT (1968), both in chemistry. He was Director of Research at the American Health Foundation and has been Wallin Professor of Cancer Prevention at the University of Minnesota, Masonic Cancer Center, since 1996. He was Head of the Carcinogenesis and Chemoprevention Program from 1997-2014 and is a member of the Molecular Pharmacology and Therapeutics graduate program. His research focuses on mechanisms and prevention of cancer induced by tobacco products and environmental agents. He has been continually funded by the National Cancer Institute since 1975 and is an American Cancer Society Research Professor. He has published over 900 papers in the scientific literature.



Roy S. Herbst, MD, PhD

Yale University

Roy S. Herbst, MD, PhD is Deputy Director for Yale Cancer Center and Chief of Medical Oncology for Yale Cancer Center and Smilow Cancer Hospital. He is Ensign Professor of Medicine at Yale School of Medicine.

Dr. Herbst has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. This work led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His leadership in targeted therapeutics resulted in a 2020 ASCO plenary talk and publication of results of the third-generation EGFR-inhibitor osimertinib for the treatment of resected EGFR-mutant NSCLC in the New England Journal of Medicine. In 2023 he presented the positive overall survival results from this trial at the ASCO plenary session published with his coauthors in the New England Journal. He and his Yale colleagues were among the first to describe the PD-1/PD-L1 adaptive immune response in early phase trials and to offer trials of PD-L1 inhibitors atezolizumab and pembrolizumab to lung cancer patients. In 2015 and again in 2020, his team at Yale was awarded a Lung Cancer SPORE (P50 grant) by the NCI, which has identified new immunotherapies and mechanisms of sensitivity and resistance to EGFR targeted therapies.

His work on "umbrella" trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he works closely with public-private partnerships to develop large master protocol clinical studies, such as Lung-MAP for which he served as the founding PI and Chair from 2013-2022 and now remains as chair emeritus. He

testified on the subject of modernizing clinical trials during the 21st Century Cures hearing before the US House of Representatives Subcommittee on Health and has served as a prominent figure in the public policy arena, for nine years having served as a member of the National Academy of Medicine's Cancer Policy Forum, for which he organized several meetings focused on policy issues in personalized medicine and tobacco control.

Dr. Herbst is a highly respected clinician- scientist who has been a champion of translational medicine for decades, recently authoring a high-profile review of the 20-year progress in lung cancer. He has authored or co-authored more than 400 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has appeared in many prominent journals, such as the *Journal of Clinical Oncology*, *Clinical Cancer Research*, *Lancet*, and the *New England Journal of Medicine*. Work published in *Nature* was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

He is a Fellow of the American Society of Clinical Oncology and a member of the American Association of Cancer Research (AACR), where he served as an elected member of its board of directors and chairs the Scientific Policy and Government Affairs Committee. He has been a major proponent of efforts to promote tobacco control and regulation (including e-cigarettes), authoring multiple policy statements and leading frequent Capitol Hill briefings. In 2019 he was elected to the International Association for the Study of Lung Cancer (IASLC) board of directors. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair of the Southwestern Oncology Group's (SWOG) Lung Committee.

For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th World Conference on Lung Cancer in Vienna, Austria. A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, was awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy.

For his lifetime achievement in scientific contributions to thoracic cancer research, Dr. Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the IASLC at their 17th World Conference on Lung Cancer in Vienna, Austria. A team of Yale Cancer Center investigators led by Roy S. Herbst, MD, PhD, was awarded the 2018 Team Science Award from the Association for Clinical and Translational Science (ACTS) for its pioneering work in advancing our understanding of Immunotherapy. In 2020, Dr. Herbst was awarded the AACR Distinguished Public Service Award for Exceptional Leadership in Cancer Science Policy.



Chanita Hughes-Halbert, PhD
University of Southern California

The goal of Dr. Hughes-Halbert's research program is to improve the precision of multilevel strategies for achieving health equity by identifying diverse determinants of minority health and cancer health disparities and by translating this information into sustainable interventions in clinic and community-based settings to improve cancer outcomes and chronic disease management in disparity populations in local and regional geographic areas. Dr. Hughes-Halbert is a nationally recognized expert in cancer prevention and control among diverse populations and her research is supported by numerous grants from the National Cancer Institute, the National Institutes on Minority Health and Health Disparities, and the Veteran's Affairs Medicine Center. Previously, she was a member of the Board of Scientific Advisors at the National Cancer Institute and the

National Human Genome Research Institute Advisory Council. Dr. Hughes-Halbert is a past recipient of the AACR Distinguished Lecture in Cancer Health Disparities Award and is a member of the National Academy of Medicine.



Farhad Islami, MD, PhD
American Cancer Society

As Senior Scientific Director, Farhad Islami, MD, PhD, leads the Cancer Disparity Research team in the Surveillance and Health Equity Science department at the American Cancer Society. He worked as a research fellow at the Digestive Disease Research Institute of Tehran University of Medical Sciences, as a scientist at the International Agency for Research on Cancer (IARC), and as a faculty member at Icahn School of Medicine at Mount Sinai before joining the American Cancer Society.

Dr. Islami's research focuses on quantifying the impact of factors that contribute to cancer disparities across the cancer continuum. He has also conducted extensive research on the risk factors of cancer that are potentially modifiable, and notably, smoking and alcohol consumption. In addition to original research on smoking and alcohol and cancer, he participated in 16 meta-analyses of alcohol consumption and cancer risk by cancer type, a collaborative project between IARC and Mario Negri Institute in Milan. His work on estimating the burden of cancer attributable to potentially preventable risk factors, including smoking and alcohol consumption, in the United States and some other countries has been widely cited by the media, academics, and policy makers. As a member of the IARC team or a working group member, Dr. Islami has been participated in nine IARC Monographs and Handbooks, including "*IARC Handbooks of Cancer Prevention Volume 20: Reduction of Alcohol Consumption*".

Dr. Islami has a MD from Tehran University of Medical Sciences and PhD in Epidemiology from King's College, London. He was a postdoctoral fellow at IARC.



Roy A. Jensen, MD
The University of Kansas Cancer Center

Roy Jensen, MD was appointed the director of The University of Kansas Cancer Center (KU Cancer Center) in 2004. As a result of a broad-based university, community, and regional effort, The University of Kansas Cancer Center was designated as a cancer center by the National Cancer Institute (NCI) in July 2012 and as a comprehensive cancer center in 2022. Dr. Jensen is currently Professor of Pathology and Laboratory Medicine, Professor of Cancer Biology, and the William R. Jewell, M.D. Distinguished Kansas Masonic Professor at the University of Kansas Medical Center. Prior to his appointment at KU Cancer Center, Jensen was a member of the Vanderbilt-Ingram Cancer Center and a faculty member in Pathology, Cell Biology, and Cancer Biology for 13 years.

Dr. Jensen graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship with Dr. David Page. Following his clinical training he accepted a postdoctoral fellowship at the NCI in the laboratory of Dr. Stuart Aaronson. After he joined the faculty at Vanderbilt University, Dr. Jensen focused his research on understanding the function of BRCA1 and BRCA2 and their role in breast neoplasia, and in the characterization of premalignant breast disease at both the morphologic and molecular levels. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology.

Dr. Jensen has served on numerous grant review panels, study sections, and site visit teams for the NIH, the Department of Defense-Breast Cancer Research Program, the Medical Research Council of Canada, the California Breast Cancer Research Program, the Susan G. Komen Breast Cancer Foundation, and the Federation of American Societies for Experimental Biology. Jensen has served on the Science Policy and Governmental Affairs Committees for the American Association for Cancer Research (AACR) and as a member of the AACR Pathology Task Force, AACR Publications Committee, and the AACR Nominating Committee. Jensen also serves as a director-at-large for the American Cancer Society Cancer Action Network Board of Directors. In 2013, he was elected to the Board of Directors for the Association of American Cancer Institutes (AACI) and served as the vice president (2016-2018), president (2018-2020), and past president of AACI from 2020-2023. Jensen served as a member of NCI's Subcommittee A from 2014-2018, chair of

Subcommittee A from 2018-2020, and also served on the Director's Working Group for the Board of Scientific Advisors to the National Cancer Institute.



Ayana Jordan, MD, PhD

New York University Grossman School of Medicine

Ayana Jordan, MD, PhD, is an endowed Barbara Wilson Associate Professor in the Department of Psychiatry, Addiction Psychiatrist and Associate Professor in the Department of Population Health at New York University (NYU) Grossman School of Medicine. As Principal Investigator for the Jordan Wellness Collaborative (JWC), she leads a research, education, and clinical program that partners with community members to provide optimal access to evidence-based treatments for racial and ethnic minoritized patients with mental health disorders.

Through her multi-faceted work, she provides addiction treatment in faith settings, studies health outcomes for people with opioid use disorder in the carceral system, and trains addiction specialists to provide culturally-informed treatment.

Dr. Jordan is dedicated to creating spaces and opportunities for more people of color, specifically Black women in academia who are vastly underrepresented. She has numerous peer-reviewed publications, has been featured at international conferences, and is the proud recipient of various clinical and research awards. Recently, Dr. Jordan received the prestigious Presidential Career Award for Scientists and Engineers, the highest honor given by the U.S. government to early career scientists and engineers. The award recognizes innovative scientific and technological developments. The fundamental message of equity and inclusion has informed her research, clinical work, and leadership duties at NYU and beyond, and she will continue to center these principles in her scholarship.



Amy C. Justice, MD, PhD

Yale University; Veterans Affairs Connecticut Healthcare System

Dr. Justice is the CNH Long Professor of Medicine and Public Health at Yale University. A Clinical Epidemiologist, she has conducted research using data from the national VA Healthcare System for three decades. She served as a VA primary care provider for two decades and Section Chief of General Medicine at the VA Connecticut Healthcare System for 13 years. Her marquee study, the Veterans Aging Cohort Study (VACS), a longitudinal study of >180,000 United States (US) veterans with and without HIV infection, has been continuously funded by US National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH) for 30 years. VACS has been instrumental in informing our understanding of the deleterious role substance use may play (in particular,

alcohol and tobacco use) in aging with and without HIV infection. As a result of this work, she led a collaborative series of papers in *The Lancet HIV* and *The Lancet Healthy Longevity* on Aging and HIV which expanded into an international summit on this topic and is now the focus of a *Lancet Commission* which she leads. Recently she has served as the national Scientific Liaison for VA-Department of Energy Research collaboration Dr. Justice has published 600+ peer reviewed manuscripts, and presented work at the United Nations, The International AIDS Society, The Royal Medical College, the White House, and Congress. She serves on International Advisory Boards of *Lancet HIV* and *Journal of the International AIDS Society*.



Brian A. King, PhD, MPH
U.S. Food and Drug Administration

Dr. Brian A. King was appointed Director of the Food and Drug Administration's Center for Tobacco Products (CTP) in July 2022. In this position, Dr. King is responsible for assuring that CTP accomplishes its public health goals and for operationalizing the Center's vision and mission as it implements the Family Smoking Prevention and Tobacco Control Act.

Dr. King has worked for nearly two decades to provide sound scientific evidence to inform tobacco control policy and to effectively communicate this information to key stakeholders, including decision makers, the media, and the general public. Prior to joining FDA, he served as the Deputy Director for Research Translation in CDC's Office on Smoking and Health, and more recently as the Executive Editor of CDC's Morbidity & Mortality Weekly

Report Series. He has authored more than 200 scientific journal articles related to tobacco prevention and control, served as Senior Associate Editor for multiple U.S. Surgeon General's Reports on tobacco, and was lead author of CDC's 2014 evidence-based guide, "Best Practices for Comprehensive Tobacco Control Programs."

Dr. King holds a Ph.D. and M.P.H. in Epidemiology from the State University of New York at Buffalo.



William Klein, PhD
National Cancer Institute

William Klein, PhD, is Associate Director of Behavioral Research at the National Cancer Institute. He leads NCI's Behavioral Research Program, which focuses on behavioral risk factors for cancer such as tobacco, diet, sedentary behavior, UV exposure, and alcohol as well as the role of basic behavioral science (e.g., emotion, stress, aging) and communication in cancer control. Dr. Klein received his PhD in Social Psychology at Princeton University in 1991 and was a tenured member of the faculty at Colby College and University of Pittsburgh before joining NCI in 2009. He is the recipient of several teaching, mentoring, and service awards. Dr. Klein's research interests fall largely under the areas of self-judgment, risk perception, risk communication, and decision making, particularly as related to behavioral risk factors for cancer and genetic testing. His work has appeared in over 250 publications and has been supported by NCI, NSF, and several private foundations. Dr. Klein holds an adjunct appointment at the National Human Genome Research Institute where he conducts

research on risk communication and decision making in the context of genetic information and serves on the Executive Committee of the NIH/Johns Hopkins genetic counseling graduate program.



Adam Leventhal, PhD
University of Southern California

Adam Leventhal, Ph.D., Professor within the Keck School of Medicine of the University of Southern California (USC), is a clinical psychologist, public health scientist, and academic administrator who advances research, education, practice, and policy that reduces addiction. He Directs the USC Institute for Addiction Science, which supports transdisciplinary collaborative addiction research and education among 80 faculty across 8 schools within the university. His research interests include: (1) adolescent and young adult substance use epidemiology; (2) addiction in priority populations; (3) science to inform public policies for regulating tobacco and other addictive consumer products; and (4) cancer and cardiovascular disease prevention. Dr. Leventhal has been awarded \$60M in research grant funding and authored over 400 peer-reviewed scientific articles on these

topics and related areas. He is active in public health service to inform addiction policy, serving on committees and other advisory roles for the National Academy of Sciences, Engineering, and Medicine, US Food and Drug Administration, US Surgeon General, White House Office of National Drug Control Policy, and World Health Organization.



Pamela Ling, MD, MPH
University of California, San Francisco

Dr. Pamela Ling is Professor of Medicine and Director of the Center for Tobacco Control Research and Education at the University of California San Francisco. Her research focuses on tobacco, media, social marketing, and young adults, and includes analyses of thousands of previously secret tobacco industry documents detailing industry marketing strategies. Her work in tobacco and alcohol includes examining integrated tobacco and alcohol industry strategies in marketing and policy, and interventions to decrease young adult tobacco use in bars and nightclubs. She has contributed to three Surgeon General's Reports on Tobacco and has been a member of the American Society for Clinical Investigation since 2016. Dr. Ling has an active clinical practice in General Internal Medicine. Fun facts: Pam Ling was on MTV's The Real World San Francisco in 1994 while

a 3rd year med student, where she met her husband, cartoonist Judd Winick. They live in Noe Valley with 2 teenage kids and 2 cats. She loves choral singing, nerd pop culture, and creative baking.



Elena Martínez, PhD, MPH
University of California, San Diego

Dr. Martinez is an epidemiologist with expertise in cancer disparities research. She is Professor in the Herbert Wertheim School of Public Health and Human Longevity Science and Associate Director of Population Sciences at UC San Diego's Moores Cancer Center. She holds the Walton Endowed Chair for Cancer Research. Nationally, she has established strong leadership and commitment to the area of cancer health disparities, particularly in relation to Hispanic/Latino populations in the U.S. Dr. Martinez is immediate past President of the American Society for Preventive Oncology. She has served on NCI's Board of Scientific Counselors and Board of Scientific Advisors and was one of 28 members nationally who served on the prestigious Cancer Moonshot Blue Ribbon Panel. She has been continuously funded by NIH as PI/MPI for over 20 years. Currently, she is multiple

principal investigator (MPI) of several NIH/NCI-funded team science research projects that focus on addressing disparities and inequities. These include, among others, the UC San Diego Faculty Institutional Recruitment for Sustainable Transformation (FIRST) award, whose goal is to promote institutional inclusive excellence by hiring a diverse cohort of early-stage faculty in biomedical sciences and the San Diego State University/UC San Diego Cancer Research and Education to Advance Health Equity (CREATE) Partnership, which focuses on addressing cancer health disparities through research, research education, and community outreach.



Nigar Nargis, PhD
American Cancer Society

In her current position at the American Cancer Society, Dr. Nigar Nargis has been serving as a Senior Scientific Director and Lead of the Tobacco Control Research team of nine full time researchers (six PhD level and three master's level) representing multiple disciplines (e.g., health science, psychology, and economics). In her prior position as a Senior Economist at the World Health Organization Headquarters, she led a team to provide technical assistance to the Ministries of Finance in Sub-Saharan countries to implement tobacco tax policy recognized as one of the most effective tobacco control measures.

Dr. Nargis is trained as an economist with focus on health, demographic and labor economics. She obtained her PhD in economics from Cornell University, USA, and bachelor's and master's degrees in economics from the University of Dhaka, Bangladesh. She specialized in tobacco control research as a postdoctoral fellow at the University of Waterloo, Canada, with the Strategic Training Program in Tobacco Research award from the Canadian Institute of Health Research.

Dr. Nargis has published extensively in leading journals on tobacco control economics and collaborated with public health

researchers from various disciplines. She is a member of several professional associations and working groups dedicated to tobacco control.



Kolawole Okuyemi, MD, MPH
Indiana University School of Medicine

Kolawole S. Okuyemi, MD, MPH, is Professor & Chair, Department of Family Medicine at Indiana University School of Medicine, Indianapolis, where he also holds the OneAmerica Professor of Preventive Health Medicine Chair and serves as Associate Dean of Health Equity Research and Implementation for the School of Medicine. Prior to coming to Indiana, he was Professor and Chair for the Department of Family and Preventive Medicine (DFPM) at the University of Utah Spencer Fox Eccles School of Medicine where he served as the George D. Gross, MD, and Esther M. Gross, MD, Presidential Endowed Chair in Family and Preventive Medicine. He also served as the Executive Director for Equity Diversity and Inclusion at the Huntsman Cancer Institute at the University of Utah. He was founding Co-Director of the Utah Health Equity Leadership & Mentoring (U-HELM) program, a yearlong, cohort-based mentoring program for postdoctoral fellows and junior faculty underrepresented in biomedical disciplines and/or active in health equity research or practice. He received his medical degree from University of Ilorin, Nigeria, completed a family medicine residency and Master of Public Health at the University of Kansas Medical

Center, Kansas City, Kansas, and a public health research fellowship at the Morehouse School of Medicine, Atlanta, Georgia.

Dr. Okuyemi's career in the last two decades is focused on research and training programs to improve the health of underserved populations and to advance health equity using medical and culturally tailored behavioral interventions as well as community-engaged research approaches. Dr Okuyemi has authored nearly 200 peer-reviewed publications. In particular, his research has focused on cancer- and smoking related health disparities experienced by African Americans, Sub-Saharan African immigrants, and persons experiencing homelessness. He was also one of the Principal Investigators awarded the NIH Common Fund grant to establish the National Research Mentoring Network for a Diverse Biomedical Workforce (NRMN), which is a nationwide consortium of biomedical professionals and institutions collaborating to provide enhanced networking and mentorship experiences in support of the career development of trainees from diverse backgrounds in biomedical, behavioral, clinical, and social science research careers. His research has been continuously funded for more than 20 years by NIH with grant awards totaling more than \$50million. Dr Okuyemi has a special commitment for mentoring and professional development and has mentored several trainees and faculty, many of whom have gone on to successful biomedical research careers.

Dr. Okuyemi has received prestigious recognition for his work, including the Hames Research Award from the Society of Teachers of Family Medicine (STFM; 2021), Lynn and Joan Carmichael Award from the STFM (2021) for Outstanding Leadership, and the Pebbles Fagan Health Award from the Society for Research on Nicotine & Tobacco (2023). Finally, Dr. Okuyemi serves on national advisory boards for several institutions including the Perlmutter Cancer Center (New York University), the Masonic Cancer Center (University of Minnesota), and Arkansas Center for Health Disparities (University of Arkansas for Medical Sciences).

Dr. Okuyemi is a board-certified family medicine physician. In his leisure time, he enjoys playing soccer, exercise, volunteering in churches and various community organizations, and spending time with his family.



Kurt M. Ribisl, PhD

University of North Carolina Gillings School of Global Public Health

Kurt M. Ribisl, Ph.D. is Jo Anne Earp Distinguished Professor and Chair in the Department of Health Behavior at the UNC Gillings School of Global Public Health at the University of North Carolina at Chapel Hill. He is also the Program Leader for Cancer Prevention and Control at UNC's Lineberger Comprehensive Cancer Center. Dr. Ribisl's primary research interest is population-level efforts to reduce tobacco use, with a particular emphasis on regulating the sales and marketing of tobacco products at retail outlets. He received his doctorate in community psychology from Michigan State University and completed a postdoctoral fellowship in cardiovascular disease prevention and epidemiology at the Stanford Prevention Research Center, Stanford University

School of Medicine. Dr. Ribisl is the author of over 230 scientific articles, and his research has been published in journals such as the American Journal of Public Health, Journal of the American Medical Association (JAMA), American Journal of Preventive Medicine, and Tobacco Control.



Lisa C. Richardson, MD, MPH

Centers for Disease Control and Prevention

Lisa C. Richardson, MD, MPH, is Director of the Division of Cancer Prevention and Control (DCPC), the largest unit within the Centers for Disease Control and Prevention's National Center for Chronic Disease Prevention and Health Promotion. As director of DCPC, she works with partners at the national, state, and local levels to break down barriers to good health and create opportunities for everyone to live a long and healthy life. Under her leadership, DCPC's four foundational programs, the National Breast and Cervical Cancer Early Detection Program, National Program of Cancer Registries, National Comprehensive Cancer Control Program, and Colorectal Cancer Control Program, have helped the cancer control community better understand, prevent and control cancer in all populations. Dr. Richardson also provides guidance for the Division's

research agenda that includes the National Cancer Prevention and Control Research Network. A medical oncologist by training, she has authored or coauthored more than 150 peer-reviewed journal articles examining multi-sectoral approaches to improving cancer care access, delivery, and outcomes.



Deidra Roach, MD

National Institute on Alcohol Abuse and Alcoholism

Dr. Roach is a general internist with more than 35 years of experience in addiction treatment. Prior to starting her federal career, she served as the Administrator and Medical Director for all government-funded addiction prevention and treatment programs in Washington, D.C., collectively known as the Addiction Prevention and Recovery Administration (APRA). She currently serves as a Program Director in the Division of Treatment, Health Services, and Recovery at the National Institute on Alcohol Abuse and Alcoholism, where, among other responsibilities, she manages research portfolios addressing the treatment of co-occurring mental health and alcohol use disorder and alcohol-related HIV/AIDS among women. Dr. Roach co-chairs the Interagency Work Group on Drinking and Drug Use in Women and Girls, a trans-DHHS

committee that promotes collaborative research and other activities focused on the prevention and treatment of substance use and co-occurring mental health disorders among women and girls. She also serves on the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders, the NIH Coordinating Committee for Research on Women's Health, and the National Academies of Sciences, Engineering and Medicine Forum on Mental Health and Substance Use Disorders, among many other committee memberships.



Harriet Rumgay, PhD

International Agency for Research on Cancer

Harriet Rumgay, PhD, is an Epidemiologist at the International Agency for Research on Cancer (IARC) - World Health Organization. Dr Rumgay works in the Cancer Surveillance Branch at IARC where she investigates the impact of modifiable risk factors on the global burden of cancer. Since 2018 her work at IARC has focused on alcohol- and tobacco-related cancers as well as cancers related with other major risk factors. Dr Rumgay's major publications include estimates of the global burden of cancer attributable to alcohol and tobacco, assessments of the global burden of primary liver cancer and oral cancer, and estimations of preventable cancers in the UK.



Benjamin A. Toll, PhD

Medical University of South Carolina

Dr. Benjamin Toll is a licensed clinical psychologist, a Professor of Public Health Sciences and Psychiatry, the Vice Chair of Research for the Department of Public Health Sciences, and the Associate Director of Education and Training and Co-Director of the Lung Cancer Screening Program at MUSC Hollings Cancer Center, and Director of the MUSC Health Tobacco Treatment Program at the Medical University of South Carolina. He specializes in clinical research on the treatment of tobacco use disorders (both cigarettes and e-cigarettes) and improvement of health behaviors.

Dr. Toll has received grants from the National Institutes of Health, including multiple RO1 grants from the National Cancer Institute, and he is an author of over 150 peer-reviewed publications relating to nicotine and tobacco research, including several large clinical trials investigating smoking cessation published in first tier medical (e.g., *Journal of the National Cancer Institute*, *Journal of Thoracic Oncology*) and psychology journals (e.g., *Journal of Consulting and Clinical Psychology*) and several pilot clinical trials testing treatments for e-cigarette use. Moreover, Dr. Toll has published multiple papers in first tier medical journals using nationally representative data showing that most e-cigarette users plan to quit vaping (in *JAMA Network Open*, *Tobacco Control*) and that e-cigarettes are used more than cigarettes by 18-24 year-olds in the US (in *JAMA Internal Medicine*), forecasting a future in which e-cigarettes are the dominant tobacco product in the US. He has over 20 articles published in high-impact journals (Impact Factor > 10), including multiple Clinical Practice Guidelines and official policy statements from major medical associations. He has served as an author for the American Association for Cancer Research (AACR) policy statement encouraging physicians to provide tobacco treatment for cancer patients, the American College of Chest Physician (CHEST) treatment guidelines for smoking cessation among lung cancer patients, the American Thoracic Society's (ATS) Clinical Practice Guideline for treatment of tobacco dependent adults, and the AACR and American Society of Clinical Oncology (ASCO) policy statement on Electronic Nicotine Delivery Systems (ENDS). He is currently Co-Chairing a Clinical Practice Guideline for CHEST that will focus on treatment guidelines for hospitalized patients who smoke. He holds leadership positions in national associations relating to nicotine and tobacco research. Dr. Toll is the President of the Society for Research on Nicotine and Tobacco (SRNT) and a member of the AACR Tobacco and Cancer Subcommittee.

Dr. Toll's NIH/NCI funded research has focused on testing novel tobacco cessation treatments, and he has conducted numerous clinical trials in this regard. Many of his studies have investigated promotion of smoking cessation through novel message framing and motivational interventions, including those delivered via telephone and in person. Dr. Toll has tested several pharmacological and counseling interventions for both cigarettes and e-cigarettes, including bupropion, naltrexone, nicotine replacement therapy, and varenicline tartrate. He also has expertise in the measurement of tobacco use and tobacco related syndromes (e.g., withdrawal, craving), and mediators and moderators of response to treatment. He has served as a reviewer for numerous peer-reviewed publications, including the Surgeon General's Report (The Health Consequences of Smoking: 50 Years of Progress, Chapter: Cigarette Smoking and Adverse Health Outcomes in Cancer Patients and Survivors). He has been quoted in many major news outlets including Time Magazine and the NY Times.

Dr. Toll's NIH/NCI funded research has focused on testing novel tobacco cessation treatments, and he has conducted numerous clinical trials in this regard. Many of his studies have investigated promotion of smoking cessation through novel message framing and motivational interventions, including those delivered via telephone and in person. Dr. Toll has tested several pharmacological and counseling interventions for both cigarettes and e-cigarettes, including bupropion, naltrexone, nicotine replacement therapy, and varenicline tartrate. He also has expertise in the measurement of tobacco use and tobacco related syndromes (e.g., withdrawal, craving), and mediators and moderators of response to treatment. He has served as a reviewer for numerous peer-reviewed publications, including the Surgeon General's Report (The Health Consequences of Smoking: 50 Years of Progress, Chapter: Cigarette Smoking and Adverse Health Outcomes in Cancer Patients and Survivors). He has been quoted in many major news outlets including Time Magazine and the NY Times.



Katrina F. Trivers, PhD, MSPH

Centers for Disease Control and Prevention

Katrina Trivers, PhD, MSPH is the Associate Director for Science in CDC's Division of Cancer Prevention and Control (DCPC) where she advises the division director in setting scientific priorities and works with division staff to maintain scientific integrity and quality in division activities. Her research interests include health equity and the epidemiology, prevention, and control of ovarian, breast, and tobacco-associated cancers. Prior to this position, she led a multidisciplinary team of health economists, health scientists, and epidemiologists in CDC's Office on Smoking and Health and provided strategic direction for research related to tobacco prevention and control. Dr. Trivers also previously coordinated and promoted use of administrative health data while in CDC's Division of Health Informatics and Surveillance and was an epidemiologist in CDC's DCPC where she

led efforts related to breast cancer in young women, cancer genomics, and ovarian cancer. She has authored or coauthored approximately 60 journal articles and is a member of the Delta Omega Honorary Society in Public Health. Dr. Trivers holds a PhD and MSPH in Epidemiology from the School of Public Health at the University of North Carolina at Chapel Hill.



Graham Warren MD, PhD, FASCO

Medical University of South Carolina

Dr. Warren is a Board-Certified Radiation Oncologist, Vice Chair for Research, and Mary M. Gilbreth Endowed Chair of Oncology at the Medical University of South Carolina (MUSC) who will be joining the University of Kentucky (UK) as Vice Chairman in the Department of Radiation Medicine and Director of the Markey Cancer Center Tobacco, Research, Universal Screening, and Treatment (TRUST) initiative. His expertise is in addressing tobacco use by cancer patients across the continuum of cancer care. He has contributed to the chapters on the effects of smoking and cessation in cancer care for the 2014 and 2020 Surgeon General's Reports and pioneered opt-out approaches to address tobacco use by cancer patients at the institutional, state, national, and international level including with working across most major cancer organizations. He has worked to change clinical practice by advancing tobacco treatment as a core component of cancer care and

participated in development and/or leadership of 3 national implementation initiatives resulting in improved care delivery affecting hundreds of thousands cancer patients over the past decade.



J. Lee Westmaas, PhD

American Cancer Society

Dr. Westmaas' research uses a social ecological framework to investigate the factors that help people quit cigarette smoking. This includes social influences (e.g., perceived availability of social support for quitting), phenotypes, personality, emotional states (e.g., depression), and health care practices. He also examines how the impact of these factors are moderated by sociodemographic characteristics such as gender, socioeconomic status and race/ethnicity. He uses results from this research to develop smoking-cessation interventions that are targeted or tailored to individuals or groups that experience tobacco-related disparities, and that can be disseminated at the population level using available digital technologies (e.g., smartphone apps, emails, etc.). Recently, Dr. Westmaas has expanded the focus of his research to include investigating the prevalence of, reasons for, and predictors of cannabis use, particularly among cancer survivors. He is also interested in investigating associations between cannabis use and anxiety, depression, overall well-being,

physical health and medical and cancer endpoints including cessation of cigarette smoking.




Robert A. Winn, MD

Virginia Commonwealth University Massey Cancer Center

Robert A. Winn, MD, is the Director of Virginia Commonwealth University (VCU) Massey Cancer Center. He is also senior associate dean for cancer innovation at the VCU School of Medicine, and professor at the Division of Pulmonary Disease and Critical Care Medicine at VCU. His current basic science research focuses on the translational aspects of the role that proliferation pathways and cellular senescence play in lung cancer. As a pulmonologist, Robert is committed to community-engaged research centered on eliminating health disparities. He is a principal investigator on several community-based projects funded by the NIH and National Cancer Institute. Robert holds a BA from the University of Notre Dame and an MD from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the

University of Colorado Health Sciences Center in Denver.



Hang Zhou, PhD

Yale School of Medicine

Hang Zhou, PhD, Assistant Professor of Psychiatry and of Biomedical Informatics & Data Science at Yale University. Dr. Zhou has a broad background in computational biology and psychiatric genetics with rich experience in genomic data analyses and inferences. Over the past years, Dr. Zhou has led several innovative projects utilizing extensive biobank-level data to unravel the genetic mechanisms shaping alcohol use disorder etiology and causal relationship with comorbid conditions including cancers.



Shu-Hong Zhu, PhD

University of California, San Diego

Shu-Hong Zhu, Ph.D. is Professor of Public Health and the Director of the Center for Research and Intervention in Tobacco Control at the University of California, San Diego. Dr. Zhu is internationally recognized for his research on the effects of tobacco quitlines. In addition to designing clinical trials testing the effects of various interventions, he conducts surveys to examine population behavior patterns. His recent work examines the interface of individual- and population-based approaches to tobacco control and how public health interventions interact with market-driven influences. Dr. Zhu has won multiple awards for his work, including the California Wellness Lecture Award and the APHA Excellence Award from the American Public Health Association.



National Cancer Policy Forum

The National Cancer Policy Forum serves as a trusted venue in which experts can identify emerging high-priority policy issues in cancer research and cancer care and work collaboratively to examine those issues through convening activities focused on opportunities for action. The forum provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden through prevention and by improving the care and outcomes for those diagnosed with cancer. Forum activities inform the cancer community and the public about critical policy issues through workshops and published reports. The forum has members with a broad range of expertise in cancer, including patient advocates, clinicians, and basic, translational, and clinical scientists. Forum members represent patients, federal agencies, academia, professional organizations, nonprofits, and industry.

The forum has addressed a wide array of topics, including

- enhancing collaborations to accelerate research and development;
- improving the quality and value of care for patients who have been diagnosed with or are at risk for cancer;
- developing tools and technologies to enhance cancer research and care; and
- examining factors that influence cancer incidence, mortality, and disparities.



Upcoming and Recent Workshops

Innovative Person-Centered Clinical Cancer Research

September 29-30, 2025

Person-centered clinical research can positively influence the outcomes of clinical research by providing a more accurate representation of real-world patient experiences. It addresses questions that are informed by patient experiences, needs, and perspectives, and involves patients in all stages of research, including design, activation, enrollment, data collection, completion, and outcome reporting. Although patient-reported outcome measures may offer potential benefits for clinical cancer research, challenges in the completeness, reliability, and validity of the data persist. This workshop will examine opportunities to overcome these challenges to advance the conduct of innovative, person-centered clinical cancer research to improve outcomes for all patients.

[Learn more and register here](#)

Strategies and Interventions to Strengthen Support for Family Caregiving and to Alleviate Caregiver Burden

Collaborative workshop convened by:

Roundtable on Quality Care for People with Serious Illness
National Cancer Policy Forum
Forum on Aging, Disability, and Independence

June 5-6, 2025

While unpaid, family caregivers can derive significant satisfaction and other positive benefits from caring for a loved one, research reveals that caregivers experience significant physical, psychological, emotional and financial burdens and a decline in their own physical and emotional health as a result of caring for people living with serious illness. This workshop will discuss evidence-based interventions and strategies that effectively address the physical, mental, and financial challenges of caregiving.

[Learn more and register here](#)

Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care

Collaborative workshop convened by:

National Cancer Policy Forum
Board on Mathematical Sciences and Analytics
Board on Life Sciences

May 20-21, 2025

The concept of cancer engineering involves the application of engineering principles to solve challenges across cancer research and cancer care. This multidisciplinary approach brings together the fields of biology, engineering, and health care to devise innovative solutions that enhance the effectiveness, accessibility, and affordability of cancer care. This workshop will consider opportunities to improve patient outcomes through the convergence of engineering with oncology practice, research, and policy.

[Learn more and register here](#)

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Collaborative workshop convened by:

National Cancer Policy Forum
Forum on Mental Health and Substance Use Disorders

March 17-18, 2025

The use of both alcohol and tobacco has independent and synergistic health effects, including links to many different cancers. There is a clear need to better understand the impact of dual use on cancer incidence and outcomes, to improve public education, and to develop oncology clinical practice guidelines for patients who use alcohol and tobacco. This workshop will examine the current state of the science and explore strategies to reduce tobacco and alcohol use to lower cancer risk and improve health outcomes.

[Learn more and register here](#)

Examining Clinical Guidelines for the Adoption of Genomic Testing

Collaborative workshop convened by:

Roundtable on Genomics and Precision Health
National Cancer Policy Forum

October 29, 2024

Clinical practice guidelines can impact adoption of new technologies into routine medical care. This workshop examined how guidelines for genomic testing are developed by various organizations, with a focus on exploring inconsistencies across guidelines and opportunities for a possible path forward for more consistent clinical guidelines for genomics to improve patient care.

[Workshop videos and presentations](#)

Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests

October 28-29, 2024

Cancer screening is considered a key cancer control strategy because patients who are diagnosed with earlier stages of disease often have better treatment options and improved health outcomes. However, effective screening tests are lacking for most cancers. The development of minimally invasive approaches to screen for multiple tumor types at once could address this unmet need, but the clinical utility of multicancer detection (MCD) testing has yet to be established.

[Workshop videos and presentations](#)

Recent Workshops

Enabling 21st Century Applications for Cancer Surveillance Through Enhanced Registries and Beyond

July 29–30, 2024

Population-based cancer surveillance has a pivotal role in assessing the nation's progress in cancer control. Cancer surveillance helps inform research and care interventions aimed at reducing the burden of cancer on patients and communities, including the ability to identify health disparities in cancer outcomes. Surveillance data are crucial for identifying emerging trends in health outcomes and opportunities to improve the quality of cancer care. However, challenges with the current approach to cancer surveillance in the United States include delays and gaps in data collection, as well as inadequate infrastructure and workforce to keep pace with the informatics and treatment-related advances in cancer. The National Cancer Policy Forum convened a public workshop to examine opportunities to enhance and modernize cancer surveillance in order to improve cancer research, care, and outcomes for all patients.

[Workshop videos and presentations](#)

[Proceedings](#)

Toward a Framework to Improve Diversity and Inclusion in Clinical Trials

Collaborative workshop convened by:

Forum on Drug Discovery, Development, and Translation
National Cancer Policy Forum

May 20, 2024

This workshop aimed to explore opportunities to improve racial and ethnic diversity in clinical trials with a focus on system-level change and collective efforts across organizations and sectors that no one entity can effectively take on alone.

[Workshop videos and presentations](#)

[Proceedings](#)

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation

March 20–21, 2024

Biological effectors of social determinants of health (SDOH) interact and impact cancer risk, treatment outcomes, and health equity. This workshop considered opportunities to advance health equity in cancer by identifying promising avenues for future research, as well as policies and interventions aimed at mitigating the negative impacts of the SDOH in cancer.

[Workshop videos and presentations](#)

[Proceedings](#)

Optimizing Public–Private Partnerships for Clinical Cancer Research

Collaborative workshop convened by:

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

October 17–18, 2023

Public–private partnerships (PPPs) have the potential to more effectively leverage public funding and resources, increase the breadth and depth of research, and affect a more rapid translation from basic discoveries to public health applications. Industry, government, nonprofit, and academic organizations could each make important and unique contributions to this endeavor. This workshop examined opportunities to enhance and foster PPPs for clinical cancer research and considered lessons learned from examples of public–private collaborations in oncology or other fields that have helped to advance clinical research and improve patient outcomes.

[Workshop videos and presentations](#)

[Proceedings](#)

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Collaborative workshop co-hosted by:

National Cancer Policy Forum
American Society of Clinical Oncology

October 5–6, 2023

2023 marked the 10-year anniversary of the Institute of Medicine report *Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis* and the ability of the cancer care delivery system to provide high-quality cancer care to all patients remains elusive. This workshop provided an opportunity for the cancer care community to discuss persistent barriers to achieving excellent and equitable cancer care for all and additional actions that could be taken to implement the 2013 recommendations. Workshop presentations and discussions also identified aspects of cancer care that have changed over the past decade and where new strategies are needed to improve the quality of care.

[Workshop videos and presentations](#)

[Proceedings](#)

Developing a Multidisciplinary and Multispecialty Workforce for Patients with Cancer, from Diagnosis to Survivorship

Collaborative workshop convened by:

National Cancer Policy Forum
Global Forum on Innovation in Health Professional Education

July 17–18, 2023

Patients living with and beyond cancer often require care from a wide range of clinicians as they navigate cancer diagnosis, treatment, and survivorship care. A multispecialty and multidisciplinary workforce is critical to ensuring that all patients with cancer receive high-quality care. This workshop examined opportunities to improve equitable access to multispecialty, multidisciplinary care for patients living with and beyond cancer.

[Workshop videos and presentations](#)

[Proceedings](#)

Forum Sponsors

Centers for Disease
Control and Prevention

National Institutes of
Health/National Cancer
Institute

American Association
for Cancer Research

American Cancer
Society

American College of
Radiology

American Society of
Clinical Oncology

Association of American
Cancer Institutes

Association of Cancer
Care Centers

Cancer Center at Illinois
Flatiron Health

Merck

National Comprehensive
Cancer Network

National Patient
Advocate Foundation

Novartis Oncology

Oncology Nursing
Society

Partners In Health

Pfizer Inc.

Forum Members

Robert A. Winn, M.D. (Chair)
Virginia Commonwealth University

Rohit Bhargava, Ph.D.
Cancer Center at Illinois

Smita Bhatia, M.D., M.P.H.
University of Alabama at Birmingham

Gideon Blumenthal, M.D.
Merck

Chris Boshoff, M.D., Ph.D.
Pfizer Inc.

Christina Chapman, M.D.
Baylor College of Medicine

Gwen Darien
National Patient Advocate Foundation

Crystal Denlinger, M.D., FACP
National Comprehensive Cancer Network

James H. Doroshow, M.D.
National Cancer Institute

S. Gail Eckhardt, M.D., FASCO
Baylor College of Medicine

Christopher R. Friese, Ph.D., R.N., AOCN®
University of Michigan

Scarlett Lin Gomez, M.P.H., Ph.D.
University of California, San Francisco

Julie R. Gralow, M.D., FACP, FASCO
American Society of Clinical Oncology

Sarah M. Greene, M.P.H.
Cancer Research Advocate

Roy S. Herbst, M.D., Ph.D.
Yale University

Hedvig Hricak, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Chanita Hughes-Halbert, Ph.D.
University of Southern California

Roy A. Jensen, M.D.
University of Kansas; Association of
American Cancer Institutes

Randy A. Jones, Ph.D., R.N., FAAN University
of Virginia

Beth Y. Karlan, M.D.
University of California, Los Angeles

Samir N. Khleif, M.D.
Georgetown University; Society for
Immunotherapy of Cancer

Ronald Kline, M.D.
Centers for Medicare and Medicaid Services

Shivaani Kummar, M.D., FACP
Oregon Health and Science University

Elena Martinez, Ph.D.
University of California, San Diego

Larissa Nekhlyudov, M.D., M.P.H.
Brigham & Women's Hospital; Dana-Farber
Cancer Institute; Harvard Medical School

Cleo A. Ryals, Ph.D.
Flatiron Health

Julie Schneider, Ph.D.
Oncology Center of Excellence, Food and
Drug Administration

Susan M. Schneider, Ph.D., R.N., AOCN®
Duke University

Lawrence N. Shulman, M.D., MACP, FASCO
University of Pennsylvania

Heidi Smith, M.H.S.
Novartis Pharmaceuticals

Amye J. Tevaarwerk, M.D.
Mayo Clinic in Rochester, Minnesota

Katrina Trivers, Ph.D., M.S.P.H.
Centers for Disease Control and Prevention

Robin Yabroff, Ph.D.
American Cancer Society

Forum Staff

RESPONSIBLE STAFF OFFICERS

Francis Amankwah, M.P.H.
Forum Co-Director

Sharyl Nass, Ph.D.
Forum Co-Director
Senior Director, Board on
Health Care Services

ADDITIONAL PROJECT STAFF

Makeda Haughton, B.A.
Senior Program Assistant

Torrie Brown, B.A.
Program Coordinator

Emma Wickland, M.P.H.
Research Associate

Julie Wiltshire, B.S.
Senior Finance Business Partner

Jennifer Zhu, M.S.
Associate Program Officer

CHRISTINE MIRZAYAN FELLOW

Lauren Giurini, Ph.D. Candidate
University of Wisconsin-Madison

NATIONAL ACADEMIES

Sciences
Engineering
Medicine

The National Academies provide
independent, trustworthy advice
that advances solutions to society's
most complex challenges.

www.nationalacademies.org

CONTACT: Jennifer Zhu ✉ jzhu@nas.edu

Board on Health Care Services
Health and Medicine Division



NATIONAL CANCER POLICY FORUM

WORKSHOP PROCEEDINGS AND RELATED PUBLICATIONS

NATIONAL
ACADEMIES

Sciences
Engineering
Medicine

Promoting Health Equity in Cancer Care



Proceedings of a Workshop


PROCEEDINGS OF A WORKSHOP

Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic



The National Academies of
SCIENCES • ENGINEERING • MEDICINE

PROCEEDINGS OF A WORKSHOP



The Impact of the Affordable Care Act on Cancer Prevention and Cancer Care

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

WORKSHOP PROCEEDINGS

2025

Opportunities and Challenges for the Development and Adoption of Multicancer Detection Tests
(In Progress)

Enabling 21st Century Applications for Cancer Surveillance through Enhanced Registries and Beyond

2024

Toward a Framework to Improve Diversity and Inclusion in Clinical Trials

Biological Effectors of Social Determinants of Health in Cancer: Identification and Mitigation

Optimizing Public-Private Partnerships for Clinical Cancer Research

Assessing and Advancing Progress in the Delivery of High-Quality Cancer Care

Developing a Multidisciplinary and Multispecialty Workforce for Patients with Cancer, from
Diagnosis to Survivorship

Incorporating Integrated Diagnostics into Precision Oncology Care: Proceedings of a Workshop

Addressing Treatment Resistance in the Development of Cancer Immune Modulator Therapeutics:
Proceedings of a Workshop

2023

The Potential Contribution of Cancer Genomics Information to Community Investigations of
Unusual Patterns of Cancer: Proceedings of a Workshop

Advancing Progress in Cancer Prevention and Risk Reduction: Proceedings of a Workshop

Realizing the Potential of Genomics across the Continuum of Precision Health Care:
Proceedings of a Workshop

2022

Family Caregiving for People with Cancer and Other Serious Illnesses: A Workshop

Innovation in Electronic Health Records for Cancer Care, Research, and Surveillance: A Workshop

Promoting Health Equity in Cancer Care: Proceedings of a Workshop

The Role of Companion Animals as Sentinels for Predicting Environmental Exposure Effects on Aging and
Cancer Susceptibility in Humans: Proceedings of a Workshop

Innovation in Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic:
Proceedings of a Workshop

Impact of the Affordable Care Act on Cancer Prevention and Cancer Care: Proceedings of a Workshop


To receive updates on the
National Cancer Policy Forum, visit:

nationalacademies.org/NCPF

#NatlCancerForum

NATIONAL
ACADEMIES

Sciences
Engineering
Medicine



WORKSHOP PROCEEDINGS

2021

- Addressing the Adverse Consequences of Cancer Treatment: Proceedings of a Workshop
- Opportunities and Challenges for Using Digital Health Applications in Oncology: Proceedings of a Workshop
- Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer: Proceedings of a Workshop— in Brief
- Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening: Proceedings of a Workshop
- Drug Research and Development for Adults Across the Older Age Span: Proceedings of a Workshop

2020

- Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward: Proceedings of a Workshop
- Applying Big Data to Address the Social Determinants of Health in Oncology: Proceedings of a Workshop
- Health Literacy and Communication Strategies in Oncology: Proceedings of a Workshop
- Enhancing Scientific Reproducibility in Biomedical Research Through Transparent Reporting: Proceedings of a Workshop

2019

- Developing and Sustaining an Effective and Resilient Oncology Careforce: Proceedings of a Workshop
- Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop
- Improving Cancer Diagnosis and Care: Clinical Application of Computational Methods in Precision Oncology: Proceedings of a Workshop

2018

- Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: Proceedings of a Workshop
- Establishing Effective Patient Navigation Programs in Oncology: Proceedings of a Workshop
- Long-Term Survivorship Care After Cancer Treatment: Proceedings of a Workshop

2017


- The Drug Development Paradigm in Oncology: Proceedings of a Workshop
- Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care: Proceedings of a Workshop
- Implementation of Lung Cancer Screening: Proceedings of a Workshop
- Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum: Proceedings of a Workshop


2016

- Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop
- Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection: Workshop Summary
- Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology: Workshop Summary

2015

- Comprehensive Cancer Care for Children and Their Families: Summary of a Joint Workshop by the Institute of Medicine and the American Cancer Society
- Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary
- Assessing and Improving the Interpretation of Breast Images: Workshop Summary
- Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary





WORKSHOP PROCEEDINGS

2014

Ensuring Patient Access to Affordable Cancer Drugs: Workshop Summary
Contemporary Issues for Protecting Patients in Cancer Research: Workshop Summary

2013

Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer: Workshop Summary
Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary
Sharing Clinical Research Data: Workshop Summary
Delivering Affordable Cancer Care in the 21st Century: Workshop Summary
Reducing Tobacco-Related Cancer Incidence and Mortality: Workshop Summary

2012

The Role of Obesity in Cancer Survival and Recurrence: Workshop Summary
Informatics Needs and Challenges in Cancer Research: Workshop Summary
Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary

2011

Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary
Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary
The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care
Nanotechnology and Oncology: Workshop Summary

2010

Direct-to-Consumer Genetic Testing (with the National Research Council): Summary of a Workshop
Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
A Foundation for Evidence-Driven Practice: A Rapid Learning System for Cancer Care: Workshop Summary
Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary

2009

Assessing and Improving Value in Cancer Care: Workshop Summary
Ensuring Quality Cancer Care Through the Oncology Workforce: Sustaining Care in the 21st Century: Workshop Summary
Multi-Center Phase III Clinical Trials and the NCI Cooperative Group Program: Workshop Summary

2008




Implementing Colorectal Cancer Screening: Workshop Summary
Improving the Quality of Cancer Clinical Trials: Workshop Summary

2007

Cancer-Related Genetic Testing and Counseling: Workshop Proceedings
Cancer in Elderly People: Workshop Proceedings
Implementing Cancer Survivorship Care Planning: Workshop Summary

2006

Effect of the HIPAA Privacy Rule on Health Research: Proceedings of a Workshop
Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: Workshop Summary



RELATED WORK

CONSENSUS STUDY REPORTS BUILDING ON NCPF WORK

Childhood Cancer and Functional Impacts Across the Care Continuum (2021)

Report: nap.edu/catalog/25944

Diagnosing and Treating Adult Cancers and Associated Impairments (2021)

Report: nap.edu/catalog/25956

Guiding Cancer Control:
A Path to Transformation (2019)

Report: nap.edu/catalog/25438

Making Medicines Affordable:
A National Imperative (2017)

Report: nap.edu/catalog/24946

Biomarker Tests for Molecularly Targeted Therapies:
Key to Unlocking Precision Medicine (2016)

Report: nap.edu/catalog/21860

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)

Report: nap.edu/catalog/21841

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013)

Report: nap.edu/catalog/18359

Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)

Report: nap.edu/catalog/13297

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010)

Report: nap.edu/catalog/12879

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010)

Report: nap.edu/catalog/12869

Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research (2009)

Report: nap.edu/catalog/12458

Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment (2007)

Report: nap.edu/read/11892

INDIVIDUALLY AUTHORED PUBLICATIONS BUILDING ON NCPF WORK





Independent, individually authored articles arising from NCPF workshops—and consensus studies building on NCPF work—include:

2024

- Herbst, R. S., G. Blumenthal, S. N. Khleif, S. M. Lippman, N. J. Meropol, K. Rosati, L. N. Shulman, H. Smith, M. Wang, R. A. Winn, and R. L. Schilsky. 2024. Optimizing public private partnerships to support clinical cancer research. *Journal of the National Cancer Institute*. 10.1093/jnci/djae279
- Nekhlyudov, L., L. A. Levit, and P. A. Ganz. 2024. Delivering high-quality cancer care: Charting a new course for a system in crisis: One decade later. *Journal of Clinical Oncology*. 42(36):4342-4351.
- Peterson, D. E., N. L. Stout, L. N. Shulman, J. Perkins, G. LeMarier, and L. Nekhlyudov. 2024. Gaps in access to medically necessary dental care for patients living with and beyond cancer: We must do better. *Journal of Clinical Oncology*. <https://doi.org/10.1200/JCO.24.00162>.
- Singh, A. P., E. P. Balogh, R. W. Carlson, M. M. Huizinga, B. A. Malin, A. Melamed, N. J. Meropol, E. D. Pisano, R. A. Winn, K. R. Yabroff, and L. N. Shulman. 2024. Re-envisioning electronic health records to optimize patient-centered cancer care, quality, surveillance, and research. *Journal of Clinical Oncology: Oncology Practice*. 10.1200/OP.24.00260.

2022

- Bono, K. and N. L. Keating. 2022. Addressing social determinants of health: Now is the time. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac137/6705076?searchresult=1>.
- Bradley, C. J., S. Kitchen, S., Bhatia, J., Bynum, G., Darien, J. L. Lichtenfeld, R. Oyer, L. N. Shulman, and L. Kennedy Sheldon. 2022. Policies and practices to address cancer's long-term adverse consequences. *Journal of the National Cancer Institute*. 114(8):1065-1071. <https://academic.oup.com/jnci/article-abstract/114/8/1065/6570605?redirectedFrom=fulltext>.
- Davidson, N. E., K. E. Knudsen, S. Fuld Nasso, R. Oyer, S. Pergam, L. Strawbridge, and L. Shulman. 2022. Cancer care at the beginning of the COVID-19 pandemic: Effects on patients and early interventions to mitigate stresses on care. *Cancer Journal* 28(2):107-110. https://journals.lww.com/journalppo/Abstract/2022/03000/Cancer_Care_at_the_Beginning_of_the_COVID_19.5.aspx.
- Fan, Q. D. Keene, M. Banegas, S. Gehlert, L. M. Gottlieb, K. R. Yabroff, C. E. Pollack. 2022. Housing insecurity among patients with cancer. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac136/6705075?searchresult=1>.
- Graboyes, E. M., K. H. Chaichatchi, J. S. Gall, W. Johnson, J. S. Krishnan, S. S. McManus, L. Thompson, L. N. Shulman, K. R. Yabroff. 2022. Addressing transportation insecurity among patients with cancer. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac134/6705073?searchresult=1>.
- Hyer, R. N. 2022. Insights for oncology trials garnered from the rapid development of an mRNA COVID-19 vaccine. *Cancer Journal* 28(2):146-150. https://journals.lww.com/journalppo/Fulltext/2022/03000/Insights_for_Oncology_Trials_Garnered_From_the.12.aspx.



2022, continued

- Karzai, F., and W. L. Dahut. 2022. Lessons from the impact of the COVID-19 pandemic at the national cancer institute: Cancer research and care. *Cancer Journal* 28(2):118-120. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons_From_the_Impact_of_the_COVID_19_Pandemic.7.aspx.
- Nekhlyudov, L., L. A. Fleisher, and P. B. Jacobsen. 2022. Telemedicine across the cancer care continuum: Evidence and opportunities for clinical care, research, and policy. *Cancer Journal* 28(2):121-124. https://journals.lww.com/journalppo/Abstract/2022/03000/Telemedicine_Across_the_Cancer_Care_Continuum.8.aspx.
- Nekhlyudov L., G. B. Campbell., K. H. Schmitz, G.A. Brooks, A.J. Kumar, P.A. Ganz, and D. Von Ah. 2022. Cancer-related impairments and functional limitations among long-term cancer survivors: Gaps and opportunities for clinical practice. *Cancer* 128(2): 222-229. <https://pubmed.ncbi.nlm.nih.gov/34529268/>.
- Oyer, R. A., L. Pierce, C. Lathan, and B. Sagar. 2022. Maintaining and advancing quality cancer care during a global pandemic. *Cancer Journal* 28(2):134-137. https://journals.lww.com/journalppo/Abstract/2022/03000/Maintaining_and_Advancing_Quality_Cancer_Care.10.aspx.
- Parikh, R. B., K. M. Basen-Engquist, C. Bradley, D. Estrin, M. Levy, J. L. Lichtenfeld, B. Malin, D. McGraw, N. J. Meropol, R. Oyer, L. Kennedy Sheldon, and L. N. Shulman. 2022. Digital health applications in oncology: An opportunity to seize. 2022. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djac108/6596055?redirectedFrom=fulltext#no-access-message>.
- Prindiville, S. A., G. A. Sarosy, D. Loose, H. Ciolino, and J. H. Doroshow. 2022. Patterns of enrollment in cancer treatment trials during the COVID-19 pandemic at national cancer institute-designated cancer centers. *Cancer Journal* 28(2):111-117. https://journals.lww.com/journalppo/Abstract/2022/03000/Patterns_of_Enrollment_in_Cancer_Treatment_Trials.6.aspx.
- Raber, M., A. Jackson, K. Basen-Engquist, C. Bradley, S. Chambers, F. N. Gany, C. Hughes-Halbert, S. T. Lindau, R. Perez-Escamilla, and H. Seligman. 2022. Food insecurity among people with cancer: Nutritional needs as an essential component of care. *Journal of the National Cancer Institute*. <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djac135/6705074?searchresult=1..>
- Rivera, D. R., P. G. Kluetz, K. Abdallah, S. Agrawal, D. C. Angus, R. M. Califf, E. Garrett-Mayer, R. Hyer, D. R. Lowy, and S. N. Khleif. 2022. Clinical evidence generation during a pandemic: Lessons learned for sustaining progress. *Cancer Journal* 28(2):151-156. https://journals.lww.com/journalppo/Abstract/2022/03000/Clinical_Evidence_Generation_During_a_Pandemic.13.aspx.
- Roberts, T. J., and I. T. Lennes. 2022. Lessons for oncology from the COVID-19 pandemic: Operationalizing and scaling virtual cancer care in health systems. *Cancer Journal* 28(2):125-133. https://journals.lww.com/journalppo/Abstract/2022/03000/Lessons_for_Oncology_From_the_COVID_19_Pandemic.9.aspx.
- Schilsky, R. L. 2022. Beyond the COVID-19 pandemic: Sustaining and improving equitable cancer care and research. *Cancer Journal* 28(2):105-106. https://journals.lww.com/journalppo/Citation/2022/03000/Beyond_the_COVID_19_Pandemic_Sustaining_and.4.aspx.
- Winkfield, K. M., and R. A. Winn. 2022. Improving equity in cancer care in the face of a public health emergency. *Cancer Journal* 28(2):128-145. https://journals.lww.com/journalppo/Abstract/2022/03000/Improving_Equity_in_Cancer_Care_in_the_Face_of_a.11.aspx

2021

- Bertagnolli, M. M. and H. Singh. 2021. Treatment of older adults with cancer - Addressing gaps in evidence. *New England Journal of Medicine* 385:1062-1065. <https://www.nejm.org/doi/full/10.1056/NEJMp2106089>.
- Housten, A. J., C. M. Gunn, M. K. Paasche-Orlow, and K. M. Basen-Engquist. 2021. Health literacy interventions in cancer: A systematic review. *Journal of Cancer Education* 36(2):240-252. <https://pubmed.ncbi.nlm.nih.gov/33155097/>.

2020

- Schilsky, R.L., S. Nass, M.M. Le Beau, and E. J. Benz, Jr. 2020. Progress in cancer research, prevention, and care. *New England Journal of Medicine* 383(10):897-990. <https://www.nejm.org/doi/full/10.1056/NEJMp2007839..>
- Shulman, L. N., L. Kennedy Sheldon, and E. J. Benz. 2020. The future of cancer care in the United States—Overcoming workforce capacity limitations. *JAMA Oncology* 6(3):327-328. <https://jamanetwork.com/journals/jamaoncology/article-abstract/2758839..>
- Panagiotou, O. A., L. Hoffman-Högg, H. Hricak, S. N. Khleif, M. A. Levy, D. Magnus, M. J. Murphy, B. Patel, R. A. Winn, S. J. Nass, C. Gatsonis, and C. R. Cogle. 2020. Clinical application of computational methods in precision oncology: A review. *JAMA Oncology* 6(8):1282:1286. <https://jamanetwork.com/journals/jamaoncology/article-abstract/2765757..>

2019

- Balogh, E. P., A. B. Bindman, S. G. Eckhardt, S. Halabi, R. D. Harvey, I. Jaiyesimi, R. Miksad, H. L. Moses, S. J. Nass, R. L. Schilsky, S. Sun, J. M. Torrente, and K. E. Warren. 2019. Challenges and opportunities to updating prescribing information for longstanding oncology drugs. *The Oncologist* 24:1-7. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/>.
- Takvorian, S. U., E. Balogh, S. Nass, V. L. Valentin, L. Hoffman-Högg, R. A. Oyer, R. W. Carlson, N. J. Meropol, L. Kennedy Sheldon, and L. N. Shulman. 2019. Developing and sustaining an effective and resilient oncology careforce: Opportunities for action, *Journal of the National Cancer Institute* 112(7):663-670. <https://doi.org/10.1093/jnci/djz239>.
- Kline, R. M., G. B. Rocque, E. A. Rohan, K. A. Blackley, C. A. Cantril, M. L. Pratt-Chapman, H. A. Burris, and L.N Shulman. 2019. Patient navigation in cancer: The business case to support clinical needs. *Journal of Oncology Practice* 15(11):585-590. <https://www.ncbi.nlm.nih.gov/pubmed/31509483>.
- Lubejko, B. G., C. Cantril, L. H. Hogg, and L. Kennedy Sheldon. 2019. Novice oncology nurse navigator: Core elements in establishing training needs and building on competencies. *Clinical Journal of Oncology Nursing* 23(4):387-394. <https://www.ncbi.nlm.nih.gov/pubmed/31322621>.
- Nass, S. J., M.B. Cohen, R. Nayar, M.M. Zutter, E. P. Balogh, R. L. Schilsky, H. Hricak, and K.S.J. Elenitoba-Johnson. 2019. Improving cancer diagnosis and care: Patient access to high-quality oncologic pathology. *The Oncologist* 24(10):1287-1290. <https://www.ncbi.nlm.nih.gov/pubmed/31366725>.
- Lopez, D., M. L. Pratt-Chapman, E. A. Rohan, L. Kennedy Sheldon, K. Basen-Engquist, R. Kline, L. N. Shulman, and E. J. Flores. 2019. Establishing effective patient navigation programs in oncology. *Supportive Care in Cancer* 27(6):1985-1996. <https://www.ncbi.nlm.nih.gov/pubmed/30887125>.
- Nass, S. J., C. R. Cogle, J. A. Brink, C. P. Langlotz, E. P. Balogh, A. Muellner, D. Siegal, R. L. Schilsky, and H. Hricak. 2019. Improving cancer diagnosis and care: Patient access to oncologic imaging expertise. *Journal of Clinical Oncology* 37(20):1690-1694. <https://www.ncbi.nlm.nih.gov/pubmed/31050908>.

2018

- Kline, R. M., N. K. Arora, C. J. Bradley, E. R. Brauer, D. L. Graves, N. Buchanan Lunsford, M. S. McCabe, S. F. Nasso, L. Nekhlyudov, J. H. Rowland, R. M. Shear, and P. A. Ganz. Long-term survivorship care after cancer treatment—summary of a 2017 National Cancer Policy Forum workshop. *Journal of the National Cancer Institute* 110(12):1300-1310. <https://www.ncbi.nlm.nih.gov/pubmed/30496448>.
- Nass, S. J., M. Rothenberg, R. Pentz, H. Hricak, A. Abernethy, K. Anderson, A. W. Gee, R.D. Harvey, S. Piantadosi, M. M. Bertagnolli, D. Schrag, and R. L. Schilsky. Accelerating anticancer drug development—opportunities and trade-offs. *Nature Reviews Clinical Oncology* 15(12):777-786. <https://www.ncbi.nlm.nih.gov/pubmed/30275514>.
- Demark-Wahnefried, W., K. H. Schmitz, C. M. Alfano, J. R. Bail, P. J. Goodwin, C. A. Thomson, D. W. Bradley, K. S. Courneya, C. A. Befort, C. S. Denlinger, J. A. Ligibel, W. H. Dietz, M. R. Stolley, M. L. Irwin, M. M. Bamman, C. M. Apovian, B. M. Pinto, K. Y. Wolin, R. M. Ballard, A. J. Dannenberg, E. G. Eakin, M. M. Longjohn, S. D. Raffa, L. L. Adams-Campbell, J. S. Buzaglo, S. J. Nass, G. M. Massetti, E. P. Balogh, E. S. Kraft, A. K. Parekh, D. M. Sanghavi, G. S. Morris, and K. Basen-Engquist. 2018. Weight management and physical activity throughout the cancer care continuum. *CA: A Cancer Journal for Clinicians* 68(1):64-89. <https://www.ncbi.nlm.nih.gov/pubmed/29165798>.

2017

- Basen-Engquist, K., C. M. Alfano, M. Maitin-Shepard, C. A. Thomson, K. H. Schmitz, B. M. Pinto, K. Stein, D. S. Zucker, K. L. Syrjala, E. Fallon, C. Doyle, and W. Demark-Wahnefried. 2017. Agenda for translating physical activity, nutrition, and weight management interventions for cancer survivors into clinical and community practice. *Obesity* (Silver Spring) 25(Suppl 2):S9-S22. <https://www.ncbi.nlm.nih.gov/pubmed/29086526>.
- Smith, G. L., P. A. Ganz, J. E. Bekelman, S. J. Chmura, J. J. Dignam, J. A. Efstathiou, R. Jagsi, P. A. Johnstone, M. L. Steinberg, S. B. Williams, J. B. Yu, A. L. Zietman, R. R. Weichselbaum, and Y.-C. Shih. 2017. Promoting the appropriate use of advanced radiation technologies in oncology: Summary of a National Cancer Policy Forum workshop. *International Journal of Radiation Oncology • Biology • Physics* 97(3):450-461. <https://www.ncbi.nlm.nih.gov/pubmed/28011046>.

2016

- Kirch, R., G. Reaman, C. Feudtner, L. Wiener, L. A. Schwartz, L. Sung, and J. Wolfe. 2016. Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine workshop highlights and next steps. *CA: A Cancer Journal for Clinicians* 66(5):398-407. <https://www.ncbi.nlm.nih.gov/pubmed/27145249>.

2015

- Nass, S. J., L. K. Beaupin, W. Demark-Wahnefried, K. Fasciano, P. A. Ganz, B. Hayes-Lattin, M. M. Hudson, B. Nevidjon, K. C. Oeffinger, R. Rechis, L. C. Richardson, N. L. Seibel, and A. W. Smith. 2015. Identifying and addressing the needs of adolescents and young adults with cancer: Summary of an Institute of Medicine workshop. *Oncologist* 20(2):186-195. <https://www.ncbi.nlm.nih.gov/pubmed/25568146>.

2014

- Bertagnolli, M. M., R. Canetta, and S. J. Nass. 2014. Expanding public-private collaborations to enhance cancer drug development: A Report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century." *Oncologist* 19(11):1179-1185. <https://www.ncbi.nlm.nih.gov/pubmed/25326161>.
- Balogh, E. P., C. Dresler, M. E. Fleury, E. R. Gritz, T. J. Kean, M. L. Myers, S. J. Nass, B. Nevidjon, B. A. Toll, G. W. Warren, and R. S. Herbst. 2014. Reducing tobacco-related cancer incidence and mortality: Summary of an Institute of Medicine workshop. *Oncologist* 19(1):21-31. <https://www.ncbi.nlm.nih.gov/pubmed/24304712>.
- Ferrell, B. R., T. J. Smith, L. Levit, and E. Balogh. 2014. Improving the quality of cancer care: Implications for palliative care. *Journal of Palliative Medicine* 17(4):393-399. <https://www.ncbi.nlm.nih.gov/pubmed/24548217>.

2013

- Ramsey, S. D., P. A. Ganz, V. Shankaran, J. Peppercorn, and E. Emanuel. 2013. Addressing the American health-care cost crisis: Role of the oncology community. *Journal of the National Cancer Institute* 105(23):1777-1781. <https://www.ncbi.nlm.nih.gov/pubmed/24226096>.
- Balogh, E. P., P. B. Bach, P. D. Eisenberg, P. A. Ganz, R. J. Green, J. C. Gruman, S. J. Nass, L. N. Newcomer, S. D. Ramsey, J. E. Schottinger, and Y. T. Shih. 2013. Practice-changing strategies to deliver affordable, high-quality cancer care: Summary of an Institute of Medicine workshop. *Journal of Oncology Practice* 9(6s):54s-59s. <https://www.ncbi.nlm.nih.gov/pubmed/29431037>.

2012


- Demark-Wahnefried, W., E. A. Platz, J. A. Ligibel, C. K. Blair, K. S. Courneya, J. A. Meyerhardt, P. A. Ganz, C. L. Rock, K. H. Schmitz, T. Wadden, E. J. Philip, B. Wolfe, S. M. Gapstur, R. Ballard-Barbash, A. McTiernan, L. Minasian, L. Nebeling, and P. J. Goodwin. 2012. The role of obesity in cancer survival and recurrence. *Cancer Epidemiology, Biomarkers & Prevention* 21(8):1244-1259. <https://www.ncbi.nlm.nih.gov/pubmed/22695735>.
- LoRusso, P. M., R. Canetta, J. A. Wagner, E. P. Balogh, S. J. Nass, S. A. Boerner, and J. Hohneker. 2012. Accelerating cancer therapy development: The importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. *Clinical Cancer Research* 18(22):6101-6109. <https://www.ncbi.nlm.nih.gov/pubmed/23065428>.

NATIONAL ACADEMIES

Sciences
Engineering
Medicine

The National Academies provide independent, trustworthy advice that advances solutions to society's most complex challenges.

www.nationalacademies.org



Forum on Mental Health and Substance Use Disorders

Behavioral health and substance-related disorders affect approximately 20 percent of Americans. Of those with a substance use disorder, approximately 60 percent also have a mental health disorder. These disorders account for a substantial burden of disability, have been associated with an increased risk of morbidity and mortality from other chronic illnesses, and can be risk factors for death by suicide, incarceration, and homelessness. They can compromise a person's ability to seek out and afford health care, and to adhere to care recommendations.

Those with mental health conditions, particularly serious disorders, and their advocates face numerous barriers to receiving quality care. Studies suggest that one-third to one-half or more of people with serious mental health disorders do not receive treatment. The most common reason for not seeking care is inability to pay. Also, fear of discrimination in housing, employment, military service, and other arenas can deter people from seeking or continuing care.

The goal of reducing reliance on long-term inpatient care in separate institutions has been more fully realized than the goal of providing adequate treatment and services in the community. Nearly 90 million Americans live in areas with a shortage of mental health professionals.

Another barrier to care is adequate training and other support for primary care providers in recognizing mental health and substance use disorders and appropriately managing patient care through direct services, referral, and collaboration. Often evidence-based psychosocial interventions are not even available as part of routine clinical care, due to issues of access to quality care, training, insurance coverage, and fragmentation of care.

The Health and Medicine Division of the National Academies of Sciences, Engineering, and Medicine's [Forum on Mental Health and Substance Use Disorders](http://www.nationalacademies.org/MHSUDForum) provides a structured environment

Upcoming Workshops

Addressing the Impact of Tobacco and Alcohol Use on Cancer-Related Health Outcomes

Collaborative convened by:

National Cancer Policy Forum

Forum on Mental Health and Substance Use Disorders

March 17-18, 2025

The use of both alcohol and tobacco has independent and synergistic health effects, including links to many different cancers. There is a clear need to better understand the impact of dual use on cancer incidence and outcomes, to improve public education, and to develop oncology clinical practice guidelines for patients who use alcohol and tobacco. This workshop will examine the current state of the science and explore strategies to reduce tobacco and alcohol use to lower cancer risk and improve health outcomes.

[Learn more and register here](#)

Applying Neurobiological Insights on Stress to Foster Resilience Across the Lifespan

Collaborative convened by:

Forum on Neuroscience and Nervous System Disorders

Forum on Mental Health and Substance Use Disorders

March 24-25, 2025

As rates of stress, anxiety, and depression increase, the need for understanding resilience, or the ability to withstand crisis, may equip individuals to navigate stress across the lifetime. This workshop will explore the application of neurobiological insights on stress for building resilience.

[Learn more and register here](#)

Innovations in Pharmacy Training and Practice to Advance Patient Care

Collaborative convened by:

Forum on Neuroscience and Nervous System Disorders

Forum on Mental Health and Substance Use Disorders

May 29-30, 2025

At a time when workforce challenges affect all healthcare professions, there is an opportunity to examine the full spectrum of pharmacists' contributions to the healthcare system. Student and staffing shortages continue to impact this profession with far-reaching implications for the industry. This workshop will discuss strategies to expand the pharmacy workforce, enhance training, and explore financially sustainable roles of pharmacists in healthcare.

[Learn more and register here](#)

Addressing Social and System Factors in Mental Health and Substance Use Disorders to Reduce Health Disparities

TBD, 2025

A workshop by the Forum on Mental Health and Substance Use Disorders will examine how health and human services structures influence access to and quality of care for mental health and substance use disorders. Discussions will explore how social and systemic factors, including healthcare infrastructure and economic stability, shape service delivery and outcomes. The workshop will highlight strategies to enhance care coordination, strengthen service linkages, and improve policies that promote equitable access to behavioral health care.

Website pending

Featured Activities

Addressing Workforce Challenges Across the Behavioral Health Continuum of Care: A Workshop

July 10-11, 2024

As gaps in mental health and substance use disorder care persist, there is an opportunity to strengthen health and human services to improve access and outcomes. Systemic challenges, including healthcare infrastructure limitations and economic instability, continue to shape service delivery and contribute to disparities. This workshop will explore strategies to enhance care coordination, expand service linkages, and improve policies that promote equitable access to behavioral health care.

[Recording and presentations](#)
[Proceedings](#)

Effective Models to Address Mental Health and Substance Use Disorders: Strategies for Successful and Equitable Abatement Using Opioid Settlement Dollars

December 5, 2024

As jurisdictions navigate the allocation of opioid settlement funds, there is an opportunity to implement strategies that ensure effective and equitable abatement. Policy decisions, care models, and access to treatment all play a critical role in maximizing the impact of these funds. This webinar explored key considerations for state and local jurisdictions, including policy implications of selected abatement interventions, effective care models for opioid and substance use disorders, and strategies to address equity in access to affordable, appropriate, and evidence-based treatments.

[Recording and presentations](#)

Addressing the Rising Mental Health Needs of an Aging Population: A Workshop

May 15-16, 2023

Existing systems are not prepared to provide the mental health care services needed by the growing population of older adults. Discussions emphasized information about wellness and prevention, social determinants of health in aging populations, the impact of workforce shortages and gaps, the need for supportive healthy communities, and strategies to promote positive mental health.

[Recording and presentations](#)
[Proceedings](#)

Innovative Data Science Approaches to Assess Suicide Risk: A Workshop

2022

Some social media platforms use AI/ML algorithms to identify users at high risk for suicide and, in some cases, notify local law enforcement to prevent imminent harm. Emerging real-time data sources, combined with advanced data science techniques, offer opportunities to strengthen upstream suicide prevention at individual, community, and population levels. While these innovations can enhance state and local intervention efforts, they may also pose unintended risks.

[Recording and presentations](#)
[Proceedings](#)

988 it is NOT just a number: Webinar Series

The launch of 988 marks a major shift in behavioral health crisis response. This webinar series explores strategies to strengthen the system, improve service integration, and promote equitable access to care. Discussions highlight innovations, policy challenges, and opportunities to enhance crisis response nationwide.

[Recording and presentations](#)

Forum Sponsors

American College of
Clinical Pharmacy
American Psychiatric
Association
American
Psychiatric Nurses
Association

American
Psychological
Association
Council on Social
Work Education
Hogg Foundation
for Mental Health

The JED Foundation
National
Association of
Addiction
Treatment
Providers
National Institute on
Alcohol Abuse and
Alcoholism (NIAAA)

National Institute on
Drug Abuse (NIDA)
National Institute of
Mental Health (NIMH)
The Office of the
Assistant Secretary
for Planning and
Evaluation (ASPE)

Substance
Abuse and
Mental
Health
Services
Administration
(SAMHSA)

Forum Members

Margarita Alegria, PhD

(Co-Chair) Harvard
Medical School,
Massachusetts
General Hospital

Rosalie L. Pacula, PhD

(Co-Chair) University of
Southern California

Patricia Arian, PhD

National Institute of Mental
Health

Carlos Blanco, MD, PhD

National Institute of Drug
Abuse

W. Perry Dickinson, PhD

University of Colorado,

Anita Everett, MD

Substance Abuse and
Mental Health Services
Administration

Richard G. Frank, PhD

Brookings Institution

Howard H. Goldman, MD, PhD

University of Maryland,
Baltimore School of Medicine

Kristin Kroeger, PhD

American Psychiatric
Association

Octavio N. Martinez, MD

Hogg Foundation for Mental
Health

Benjamin Miller, PsyD

Stanford School of Medicine

Kathy Pham, PharmD

American College of
Clinical Pharmacy

Annie Peters, PhD

National Association of
Addiction Treatment Providers

Deidra Roach, MD

National Institute on Alcohol
Abuse and Alcoholism

Julie Seibert, PhD

National Committee for
Quality Assurance

Ruth Shim, PhD

University of California, Davis

Matthew Tierney, MS, NP

American Psychiatric Nurses
Association

Halaevalu Vakalahi, PhD

Council on Social Work
Education

Aaron Weiner, PhD

American Psychological
Association

Forum Staff

Allie Andrada Silver, MA

Forum Director

Sharyl Nass, PhD

Senior Director

Board on Health Care Services

**NATIONAL
ACADEMIES** *Sciences
Engineering
Medicine*

The National Academies provide
independent, trustworthy advice
that advances solutions to society's
most complex challenges.

www.nationalacademies.org

CONTACT: Allie Andrada Silver, AAndradaSilver@nas.edu

Board on Health Care Services
Health and Medicine Division

Upcoming Workshop

Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care: A Workshop

May 20-21, 2025

National Cancer Policy Forum
Board on Mathematical Sciences and Analytics
Board on Life Sciences

Lecture Room
National Academy of Sciences Building
2101 Constitution Ave NW
Washington, DC 20418

Workshop Background

The concept of cancer engineering involves the application of engineering principles to solve challenges across cancer research and cancer care. This multidisciplinary approach brings together the fields of biology, engineering, and health care to devise innovative solutions to promote the delivery of high-quality cancer care. This workshop will consider opportunities to improve patient outcomes through the convergence of engineering with oncology research, practice, and policy.

This workshop will feature presentations and panel discussions on topics such as:

- Strategies to break down disciplinary silos and promote convergence in engineering and cancer research and care.
- Consideration of technologies and interventions that apply engineering approaches to accelerate cancer research and to improve care and outcomes for patients with cancer.
- Examples of the challenges and opportunities to translate advances from engineering into technologies that enable precision cancer research and care.
- Strategies to ensure that advances in cancer engineering are broadly disseminated.
- Approaches to facilitate broad access to the output of cancer engineering to promote the delivery of high-quality care, particularly in community-based settings of care.
- Opportunities to develop and expand the cancer engineering workforce, including leadership development, multidisciplinary education and training, collaborative research approaches, and use of dissemination and implementation science strategies.

Student Poster Session will be held on May 20, 2025, from 4:30 – 5:30pm ET in the Great Hall and East Court

Planning Committee

Hedvig (Hedi) Hricak, Memorial Sloan-Kettering Cancer Center (Co-Chair)
Roderic Pettigrew, Texas A&M University (Co-Chair)
Rohit Bhargava, Cancer Center at Illinois (Co-Chair)
Bissan Al-Lazikani, MD Anderson Cancer Center
Justin E. Bekelman, University of Pennsylvania
Christina Chapman, Baylor College of Medicine
Rohan Fernandes, The George Washington University
Hadiyah-Nicole Green, Ora Lee Smith Cancer Research Foundation
Phillip Sharp, Massachusetts Institute of Technology
Bruce J. Tromberg, National Institute of Biomedical Imaging and Bioengineering

[Workshop Website](#)

Upcoming Workshop

Strategies and Interventions to Strengthen Support for Family Caregiving and to Alleviate Caregiver Burden: A Workshop

June 5-6, 2025

Roundtable on Quality Care for People with Serious Illness
National Cancer Policy Forum
Forum on Aging, Disability, and Independence

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

Workshop Background

A National Academies of Sciences, Engineering, and Medicine planning committee will organize a 1.5-day public workshop that will examine evidence-based interventions and strategies that effectively address the physical, mental, and financial burdens of caregiving for cancer and other serious illnesses, with an emphasis on the role of palliative care. The workshop will feature invited presentations and panel discussions to explore the following topics:

- Strategies and interventions to address the range of challenges associated with caregiving: psychological, emotional, physical, and financial/economic burden, including increased risk of suicide among caregivers
- The critical role of palliative care in interventions to ease caregiver burden
- Special needs of different caregiver populations (e.g., children, older adults)
- Ways to scale and spread successful programs and interventions
- Policy opportunities to support family caregivers, including employer/workplace-based policies and programs

The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Planning Committee

Peggy Maguire, Cambia Health Foundation (Chair)
Alison N. Barkoff, Milken Institute School of Public Health George Washington University
Jori F. Bogetz, University of Washington School of Medicine
Rita Choula, AARP Public Policy Institute
Temeika Fairley, Centers for Disease Control and Prevention
Rory Farrand, National Alliance for Care at Home
Jeffrey T. Garland, Association of Professional Chaplains
Sharon B. Hamill, California State University Shiley Haynes Institute for Palliative Care
Rebecca A. Kirch, National Patient Advocate Foundation
Kashelle Lockman, University of Iowa Carver College of Medicine
Jason Resendez, The National Alliance for Caregiving
Susan M. Schneider, Duke University

[Workshop Website](#)

Upcoming Workshop

Innovative Person-Centered Clinical Cancer Research: A Workshop September 29-30, 2025

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

Workshop Background

Person-centered clinical research can positively influence the outcomes of clinical research by providing a more accurate representation of real-world patient experiences. It addresses questions that are informed by patient experiences, needs, and perspectives, and involves patients in all stages of research, including design, activation, enrollment, data collection, completion, and outcome reporting. Although patient-reported outcome measures may offer potential benefits for clinical cancer research, challenges in the completeness, reliability, and validity of the data persist. This workshop will examine opportunities to overcome these challenges to advance the conduct of innovative, person-centered clinical cancer research to improve outcomes for all patients.

The workshop will feature invited presentations and panel discussions on topics that may include:

- Challenges in enabling clinical cancer research, and opportunities to enhance person-centeredness and innovation in clinical cancer research.
- Strategies to embed person-centered principles across the design and conduct of clinical cancer research, including:
 - prioritization of research questions and outcomes that matter to patients,
 - inclusion of validated quality-of-life endpoints, and
 - patient involvement in the design and conduct of clinical studies, as well as reporting of study results.
- Challenges and opportunities to routinely collect, report, and act on patient-reported outcome measures in clinical cancer research.
- Ways to support the oversight and regulation of novel person-centered clinical research methods.
- Opportunities to expand availability of clinical cancer research to patients, especially in community settings of care.

Provisional Planning Committee

Gwen Darien, Patient Advocate Foundation (Co-Chair)
Lawrence Shulman, University of Pennsylvania (Co-Chair)
Gideon Blumenthal, Merck
Gail Eckhardt, Baylor College of Medicine
Roy Herbst, Yale University
Randy Jones, University of Virginia
Shivaani Kummar, Oregon Health & Science University
Megan O'Meara, Pfizer Oncology
Larissa Nekhlyudov, Brigham & Women's Hospital, Dana-Farber Cancer Institute,
and Harvard Medical School
Cleo Ryals, Flatiron Health
Richard Schilsky, American Society of Clinical Oncology
Ann Taylor, Comanche Biopharma
Robert Winn, Virginia Commonwealth University

[Workshop Website](#)

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

Purpose

To prohibit discrimination, harassment, and bullying for all participants in National Academies activities.

Applicability

All participants in all settings and locations in which the National Academies work and activities are conducted.

Preventing Discrimination, Harassment, and Bullying: Policy for Participants in National Academies Activities

The National Academies of Sciences, Engineering, and Medicine (National Academies) are committed to the principles of integrity, civility, and respect in all of our activities. We look to you to be a partner in this commitment by helping us to maintain a professional and cordial environment. **All forms of discrimination, harassment, and bullying are prohibited in any National Academies activity.** This policy applies to all participants in all settings and locations in which the National Academies work and activities are conducted, including committee meetings, workshops, conferences, and other work and social functions where employees, volunteers, sponsors, vendors, or guests are present.

Definitions

Discrimination is prejudicial treatment of individuals or groups of people based on their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws.

Sexual harassment is unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature that creates an intimidating, hostile, or offensive environment.

Other types of harassment include any verbal or physical conduct directed at individuals or groups of people because of their race, ethnicity, color, national origin, sex, sexual orientation, gender identity, age, religion, disability, veteran status, or any other characteristic protected by applicable laws, that creates an intimidating, hostile, or offensive environment.

Bullying is unwelcome, aggressive behavior involving the use of influence, threat, intimidation, or coercion to dominate others in the professional environment.

Reporting and Resolution

Any violation of this policy should be reported. If you experience or witness discrimination, harassment, or bullying, you are encouraged to make your unease or disapproval known to the individual at the time the incident occurs, if you are comfortable doing so. You are also urged to report any incident by:

- Filing a complaint through the National Academies Complaint Intake Form (<https://nas.hracity.net/webform/index/a5ed0226-f5e5-4da4-be0d-1daf8976f594>), and/or
- Filing a complaint with the Office of Human Resources at 202-334-3400 or hrservicecenter@nas.edu, or
- Reporting the incident to an employee involved in the activity in which the member or volunteer is participating, who will then file a complaint with the Office of Human Resources.

Complaints should be filed as soon as possible after an incident. To ensure the prompt and thorough investigation of the complaint, the complainant should provide as much information as is possible, such as names, dates, locations, and steps taken. The Office of Human Resources will investigate the alleged violation in consultation with the Office of the General Counsel.

If an investigation results in a finding that an individual has committed a violation, the National Academies will take the actions necessary to protect those involved in its activities from any future discrimination, harassment, or bullying, including in appropriate circumstances **the removal of an individual from current National Academies activities and a ban on participation in future activities.**

Confidentiality

Information contained in a complaint is kept confidential, and information is revealed only on a need-to-know basis. The National Academies will not retaliate or tolerate retaliation against anyone who makes a good faith report of discrimination, harassment, or bullying.

Responsible Party

The NRC Executive Officer is responsible for oversight of and substantive changes to the policy.